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Abstract
Neuroplasticity is a key factor in post-stroke functional recovery. A chief
inhibitor of post-stroke neuroplasticity is the expression of chondroitin sulfate
proteoglycans (CSPGs). Recent research has shown that the transcription factor SOX9 is
responsible for upregulating the expression of CSPGs in the injured central nervous
system. Accordingly, CSPG levels are significantly lower in mice with the Sox9 gene
conditionally knocked out. The purpose of this study was to determine how Sox9 ablation
affects neuroplasticity and recovery after stroke. Behavioural test results revealed that
Sox9 KO mice exhibited significantly improved functional recovery after stroke
compared to controls. This correlated with increased contralesional corticofugal
plasticity in the Sox9 KO animals, as highlighted by tract tracing studies. An increase in
one type of glutamatergic input marker (VGLUT1) was observed at the deafferented red
nucleus of the Sox9 KO mice, but not at the denervated the cervical spinal cord ventral
horn. Further investigation into the effects of Sox9 ablation on post-stroke
neuroplasticity would be beneficial to determine the potential of Sox9 as a therapeutic
target.
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Chapter 1:

Introduction
1.1

Stroke prevalence
A stroke is defined as a sudden loss of brain function due to an interruption in

blood supply to the brain. Stroke is a leading cause of death worldwide, second only to
ischemic heart disease (WHO 2013). Despite the fact that many risk factors for stroke
are modifiable (hypertension, activity level, weight etc.), stroke is the third leading cause
of death, and the leading cause of long-term disability in adults in Canada (CSN 2012;
StatsCan 2012). There are three main types of stroke: ischemic stroke (lack of blood
flow), intracerebral hemorrhage (bleeding within the brain), and atraumatic subarachnoid
hemorrhage (rupture of an aneurysm at the base of the brain). All three types of stroke
can lead to loss of function, but they differ in the subsets of people they usually affect, as
well as their causes, treatments, and outcomes. It is a debilitating condition that not only
puts significant strain on the approximately 300,000 individuals living with the effects of
a stroke in Canada (as well as their family members), but which also burdens the
economy (PHAC 2009). Stroke costs approximately $3.6 billion per year in Canada in
health care expenditures, as well as lost economic output and productivity due to longterm disability and premature mortality (PHAC 2009; PHAC 2011). While it is
imperative to continue to place emphasis on stroke prevention, such high rates of
disability and death due to stroke indicate that new approaches to treatment must be
investigated as well.

1.2

Risk factors and causes of ischemic stroke
Ischemic stroke (which is modeled in this study) is described as the blockage of a

vessel that supplies blood to the brain. This results in the deprivation of vital glucose and
oxygen to the most metabolically active organ in the body. It is the most common type of
1

stroke and accounts for about 80% of all cases in Canada, while the rest are hemorrhagic
(CSN 2011; Lu 2011). There are both potentially modifiable and non-controllable risk
factors for ischemic stroke. The most significant risk factor for stroke is a person’s age,
which is non-modifiable. After 55 years of age, the risk of stroke doubles every decade
for both men and women (Sacco, Benjamin et al. 1997; Gorelick and Ruland 2010).
More women than men tend to die of stroke each year despite the rate of stroke being
1.25 times higher in men. This can be attributed to the fact that women tend to live
longer than men do (Sacco, Benjamin et al. 1997). Heredity also plays a role in a
person's risk for ischemic stroke, as increased incidence of stroke among families has
been observed. Reasons for this may include heredity of genetic factors that increase
susceptibility for risk factors of stroke itself, or family members' exposure to common
predisposing environmental and lifestyle factors. In the same way, some ethnicities are
known to experience higher rates of incidence and mortality with ischemic stroke. For
example, people of African-American descent are more than twice as likely to die of
ischemic stroke than Caucasian people; however, this too may also be due to a
combination of inherited factors other than race, and environmental factors (Sacco,
Benjamin et al. 1997).
Hypertension is considered the most important modifiable risk factor for ischemic
stroke. A number of studies have shown that treating hypertension in patients
significantly lowers the incidence of stroke among them; data combined from seventeen
treatment trials of hypertension worldwide show a 38% reduction in stroke and a 40%
reduction in fatal stroke (Sacco, Benjamin et al. 1997). Certain cardiac diseases are also
known to increase the incidence of stroke, with atrial fibrillation (irregular heart rhythm)
being the most notable, which occurs in almost half of all patients who experience a
cardioembolic stroke. Cigarette smoking is known to double a person's risk of suffering
an ischemic stroke. Other modifiable risk factors include living a sedentary lifestyle,
obesity, diabetes, and hypercholesterolemia, all of which increase a patient's
susceptibility for atherosclerosis (Sacco, Benjamin et al. 1997; Lu 2011). The occurrence
of transient ischemic attacks can also serve as a warning sign for a future ischemic stroke
(Lu 2011).
2

Whether they are modifiable or not, these risk factors can contribute to the
primary causes of ischemic stroke: embolism, or thrombosis. Systemic hypoperfusion
can also cause ischemia in the brain, but is less common, and results from decreased
cardiac output or hypovolemia (Rovira, Grive et al. 2005). The model used in this
research project aims to emulate the majority of ischemic strokes, caused by embolism or
thrombosis. About twenty-five percent of ischemic strokes are due to embolism, which
occurs when a cerebral artery is blocked by a clot or debris that travels from a distant site
in the body (e.g. cardioembolic stroke occurs when a clot from the heart dislodges and
travels to the brain). Emboli can come from the heart (as mentioned), arteries, and veins,
and often occur with medical conditions that lead to abnormally increased tendencies of
blood clotting (e.g. antiphospholipid syndrome, deficiencies of anti-clotting factors,
supplemental estrogen use, etc.) (Sacco, Benjamin et al. 1997). Emboli can develop on
diseased, damaged or prosthetic valves, and atheroslerotic emboli that cause ischemic
stroke commonly come from the aortic arch or extracranial arteries. About fifty percent
of ischemic strokes are due to thrombosis, in which a thrombus (blood clot), occludes a
cerebral artery (Lu 2011). Large-vessel thrombotic strokes are the most common, and are
often due to long-term atherosclerosis followed by a rapid blood clot formation. Less
commonly, thrombotic strokes in small arteries occur, leading to lacunar infarctions
(Zorowitz R 2004).

1.3

Treatments and outcomes of ischemic stroke
Current treatments for ischemic stroke range from acute (within a few hours of

stroke onset) to long-term rehabilitation. Currently, the only FDA and Health Canadaapproved drug for ischemic stroke treatment is tPA, or recombinant human tissue
plasminogen activator, which is considered the gold standard of acute treatment. Tissue
plasminogen activator is the major enzyme involved in the breakdown of blood clots,
which catalyzes the conversion of plasminogen to plasmin and is most commonly
delivered intravenously. A tPA clinical study by the National Institute of Neurological
Disorders and Stroke found that, although there was an increased risk for intracerebral
hemorrhage to occur with the delivery of tPA, patients who received it within the correct
3

window of time experienced a 12% increase in excellent functional outcome and a 4%
risk reduction in mortality (NINDS 1995). Unfortunately, only a small percent of
ischemic stroke patients (estimated at 3%) receive this drug due to it's very narrow time
window for safe administration, which is 3-4.5 hours post-onset of stroke (Lansberg,
Bluhmki et al. 2009; Armstead WM 2010). People who experience a stroke may not
recognize their symptoms as being indicative of a medical emergency (e.g. unilateral
numbness or weakness of the face, arm or leg, visual problems, difficulty speaking or
understanding speech, dizziness, etc.) and may delay seeking medical attention (Moser,
Kimble et al. 2006; Lu 2011). Even upon arrival at a hospital, it is necessary to perform a
non-contrast head CT to determine whether symptoms are due to an ischemic or
hemorrhagic stroke, or an altogether different neuropathology (e.g. tumour, abscess) (Lu
2011). After this initial 3 - 4.5 hour time point, IV tPA treatment to breakdown blood
clots is considered ineffective in reducing the amount of infarcted tissue, and increases
the risk for intracerebral hemorrhage to occur (NINDS 1995).
Intra-arterial thrombolytic delivery is another option for treatment, and stretches
the treatment time window to about six hours after the onset of ischemic stroke. This
method involves inserting a microcatheter into the vasculature and delivering
thrombolytics locally to the site of the occlusion. This is usually a 1 to 2 hour process
that involves simultaneous angiographic imaging. As such, intra-arterial thrombolytic
treatment is a much more complicated process than IV tPA therapy, and requires more
medical professionals and equipment on hand than the latter; however, it boasts overall
superior recanalization rates of major cerebrovascular occlusions compared to tPA, most
significantly with large vessel occlusions. There are current clinical trials investigating
the combinatorial treatment of tPA and intra-arterial thrombolytic delivery (Grigoryan
and Qureshi 2010).
For a number of reasons, IV delivery of tPA may fail, or a patient may simply be
ineligible for thrombolytic therapy because the risk for intracerebral hemorrhage or other
complications would be too high. In such cases, there are endovascular surgical
treatment options. An endovascular thrombectomy involves threading a flexible wire
with helical loops into the thrombus and retrieving it. Endovascular thromboaspiration is
4

another clot extraction approach that combines aspiration and debulking of the thrombus
in an attempt to reduce or eliminate clotting. Finally, angioplasty with stent placement is
another endovascular option that is still being assessed. Each treatment approach comes
with a unique set of procedural complication risks, such as vessel rupture and distal
embolization. Many factors must go into consideration when choosing the best option for
each patient (Grigoryan and Qureshi 2010).
Time is very much so of the essence when a stroke occurs. Unfortunately, even
receiving emergency medical care may not be enough to prevent ischemic brain damage
from occurring, which can lead to disability and even death. In a study outlined by the
Canadian Stroke Network (a review of hospital records across Canada between April 1,
2008 to March 31, 2009), the in-hospital mortality rate for patients admitted for ischemic
stroke was 14% after 30 days in the hospital (CSN 2011). The mortality rates for stoke
have declined over the past few decades; however, this means that survivors are
increasingly likely to live with functional and cognitive impairments and disabilities.
The disabling aspects of stroke seem to be feared more than possible fatality, as surviving
stroke victims have stated that they believe that severe disability would be a worse
outcome than death (PHAC 2009). Unfortunately, more than half of all long-term stroke
survivors (>6 months) acquire some sort of disability (mild to severe), which contributes
to lower quality of life (Sacco, Benjamin et al. 1997; Clarke, Marshall et al. 2002; PHAC
2009).
Beyond drug and surgical therapies for ischemic stroke, rehabilitation has proved
to be beneficial for functional recovery. More specifically, physiotherapy is one of the
most important disciplines in interdisciplinary stroke rehabilitation. Physiotherapy
usually starts within the first few days after the onset of stroke, and often continues into
the chronic phase. The main goal of post-stroke physiotherapy is to re-establish the
patient's ability to independently perform basic activities of daily living, such as feeding,
bathing, dressing, and being mobile (Veerbeek, van Wegen et al. 2014). A number of
studies and meta-analyses emphasize that higher intensities and quantities of physical
therapy practices after stroke lead to better results in terms of functional recovery
(Veerbeek, van Wegen et al. 2014). Although a particular method of physiotherapy has
5

yet to be determined to be superior to others, constraint-induced movement therapy has
shown promising results. This involves restraining the limb unaffected by the stroke and
intensively using the affected limb (Johansson 2000).
Repetition is key to motor learning, and echoes the Hebbian learning rule that
connections between neurons are strengthened when they are activated simultaneously
(e.g. long term potentiation) (Veerbeek, van Wegen et al. 2014). The main concept of
post-stroke physiotherapy involves the use of exercise to induce activity-dependent
modification of synaptic connections and reorganization of cortical areas (Johansson
2000). Unfortunately, certain factors in the post-stroke central nervous system work
against this beneficial neuroplasticity. Even with physiotherapy, it is estimated that only
about half of all stroke survivors are able to perform all activities of daily living without
relying on assistance from others in the long term (Veerbeek, van Wegen et al. 2014). In
summary, the drug-based, surgical, and rehabilitative therapies currently available to treat
ischemic stroke patients do not add up to a cure, and different avenues of treatment need
to be investigated.

1.4

Ischemic injury to the central nervous system
Due to cortical neurons' high metabolic rates and energy substrate limitations

(near-exclusive dependence on glucose), the effects of ischemia in the brain are
immediate. Within seconds under ischemic conditions, cortical activity local to the
embolus or thrombus ceases as the neurons undergo an energy saving response.
Transient plasma membrane hyperpolarization due to excessive K+ efflux occurs,
followed by another dramatic rearrangement of ions across the plasma membrane. This
anoxic membrane depolarization causes the brain's normal cell-to cell signaling
mechanisms to turn dangerous. The resulting excessive release of neurotransmitters
(glutamate in particular) is a major cause of ischemic neuronal death. Massive glutamate
release (initially by activated glutamatergic neurons, and later by reverse transport by
astrocytes) involves the overstimulation of glutamate receptors. This causes glutamate
receptor ion channels to allow an excess of Ca+, Na+, and water into the cell, which is
6

particularly damaging for neurons. Excess dopamine release can also contribute to
neuronal death. This excitotoxicity encourages the spread of cellular depolarization, the
depletion of energy stores, and the progression of cell injury cascades. (Lee, Grabb et al.
2000; Moskowitz, Lo et al. 2010).
This is where the concept of the ischemic core and penumbra comes into play.
The ischemic core is defined as the area of the brain surrounding the embolus or
thrombus where revival of tissue viability is not possible; the ischemic conditions have
caused neuronal death. The ischemic penumbra, on the other hand, is an area
surrounding the core where mild to moderate hypoperfusion exists. The neurons of this
area cannot maintain their electrical activity to function normally; however, their ion
channels are preserved so that the neurons can theoretically revert to normal functionality
if blood flow is returned in a timely manner (generally within several hours of onset).
Despite the obvious merits of post-ischemic reperfusion achieved by delivery of tPA or
natural breakdown of the vessel blockage, it also brings its own brand of tissue damage
risk in the form of reactive oxygen species (superoxide, hydroxyl, and nitric oxide
radicals , etc.) and increased inflammation (Lee, Grabb et al. 2000).
Reactive oxygen species wreak havoc on the integrity of vital cellular components
(such as DNA, lipids, proteins and enzymes, etc.), and further deplete cellular energy
stores. The production of reactive oxygen species is also stimulated by other ischemic
developments, such as Zn+ overload and glutamate toxicity (Lee, Grabb et al. 2000).
Inflammation is another consequence of ischemia and reperfusion that can worsen tissue
injury. Cytokine production is increased, and the invasion of neutrophils ensues,
followed by macrophages and monocytes. This leads to microvascular obstruction as
well as the production of toxic mediators by activated inflammatory and glial cells of the
CNS. All in all, the excitotoxicity, spreading depression, oxidative stress and
inflammation within the ischemic tissue ultimately lead to cell death by apoptosis and
necrosis. Despite the creation of reactive oxygen species and increased inflammation,
reperfusion is still considered ideal for revival of the penumbra if achieved in time (Lee,
Grabb et al. 2000). Functional loss experienced after a stroke depends on the extent of
the ischemic damage, and the area in the brain in which it occurs.
7

1.5

Neuroplasticity in the post-stroke CNS, and how it relates to recovery
Neuronal death translates into loss of sensory and motor function, so central

nervous system protection is a primary goal in stroke treatment. Despite the level of the
success that acute neuroprotective and rehabilitative treatment strategies have attained,
there are still many limitations. As such, another important area of research centers on
understanding the endogenous restorative processes of the post-stroke central nervous
system, so that we may develop ways to augment and facilitate these processes to
improve recovery (Moskowitz, Lo et al. 2010). Recovery after stroke is variable, but
most sensory and motor recovery is generally observed within the first six months, (Wade
and Hewer 1987; Bonita and Beaglehole 1988; Reding and Potes 1988; Murphy and
Corbett 2009). Similar patterns of spontaneous recovery (further augmented by
rehabilitative therapy) can be seen in animal models, although the improvements seem to
occur over a much shorter period of time than in humans (Murphy and Corbett 2009).
Under normal circumstances, motor and sensory cortices are loosely organized into
functional maps, which can undergo modifications and plastic changes by experience and
use. When stroke causes damage to these regions, it has been shown that the CNS
undergoes a more pronounced "re-mapping" as recovery occurs (Murphy and Corbett
2009).
Many correlations between recovery of function and post-stroke neuroplasticity in
both the peri-infarct and more distant, unaffected parts of the CNS have been documented
in the literature. For example, a number of functional MRI studies have shown that periinfarct areas are highly active during recovery in both humans and animal models
(Dijkhuizen, Singhal et al. 2003; Chopp, Zhang et al. 2007). Other findings in human
and animal models describe how partial recovery of hemiparesis (caused by a stroke
involving the contralateral primary motor cortex) often involves either the activation of
regions in the opposite undamaged hemisphere, or the activation of undamaged neurons
ipsilateral to the stroke that are recruited to serve new functions (Pineiro, Pendlebury et
al. 2001; Feydy, Carlier et al. 2002; Schaechter, Kraft et al. 2002; Small, Hlustik et al.
2002; Dijkhuizen, Singhal et al. 2003; Fujii and Nakada 2003; Zemke, Heagerty et al.
2003). Indeed, to the extent that recovery occurs, neural function compromised by
8

ischemic injury seems to be reallocated to parallel pathways or to new alternate pathways
by way of neuroplasticity: structural changes in surviving neurons leading to the creation
of new neural connections, as well as altered electrical patterns in already existing
connections (Lee, Kim et al. 2004; Murphy and Corbett 2009; Moskowitz, Lo et al.
2010).
Neurogenesis is another process in the post-stroke CNS that may play a part in
recovery. After cerebral ischemia, newborn neurons originating from the subventricular
and subgranular zones in adult mammalian brains (which normally migrate to the
hippocampal and olfactory areas) travel towards damaged brain tissue (Arvidsson, Collin
et al. 2002; Parent, Vexler et al. 2002). However, many of these newborn cells only
survive for a few days, and it is unclear if those that survive contribute significantly to
post-stroke recovery. Further research is needed to determine whether or not they
develop normally, express neurotransmitters, or become part of functional neural
networks (Moskowitz, Lo et al. 2010). It is also fitting to discuss angiogenesis along
with neurogenesis, as similar mediators and pathways are involved in both phenomena
(Moskowitz, Lo et al. 2010). New neuronal networks are only possible if suitable
vascular networks can be established to support them. As such, it is likely that CNS
recovery after stroke relies on interdependent neurovascular re-modeling and plasticity
that are guided by similar mediators and signals (Murphy and Corbett 2009; Snapyan,
Lemasson et al. 2009).
In accordance with the theory that new cells may contribute to new circuits, stem
cell therapy has been an appealing avenue of stroke research. However, the improved
functional outcome after brain ischemia often seen with stem or progenitor cell
administration (e.g. intravenous administration of bone marrow stromal cells in rats) is
most likely due to the production of trophic factors by these cells instead of
differentiation into neuronal cells (Chen, Li et al. 2001; Murphy and Corbett 2009). The
trophic factors released enhance axonal sprouting, the elaboration of dendrites and spines,
angiogenesis, and other processes that are important for neuroplasticity; so in extension,
these studies further prove the benefits of a plastic CNS for post-stroke recovery, and that
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it is important to keep all cell types in mind when examining recovery (neural, glial, and
vascular) (Murphy and Corbett 2009).
Accordingly, in principle it would be beneficial to supply the damaged CNS with
increased amounts of these trophic factors to augment recovery. The administration of
nerve growth factor (NGF), fibroblast growth factor (FGF), glial-derived neurotrophic
factor (GDNF), and brain-derived neurotrophic factor (BDNF), for instance, to improve
post-stroke recovery have been met with variable levels of success in animal models
(Semkova and Krieglstein 1999). Also of interest are proteins that encourage growth
related processes, such as growth-associated protein 43 (GAP-43), myristoylated alaninerich C-kinase substrate (MARCKS), and brain-abundant signal protein 1 (BASP1)
(Murphy and Corbett 2009). Unfortunately, many of these growth-promoting molecules
factors are relatively large, making transport past the blood-brain-barrier into the
damaged CNS challenging. Further research is needed to optimize trophic and/or
pharmacologic factor delivery methods (e.g. using smaller peptides, or transnasal
delivery to bypass blood-brain-barrier). Another option would be to focus on compounds
that can upregulate the production of endogenous trophic factors (Moskowitz, Lo et al.
2010).
The benefits of neuroplasticity and its associations with recovery in the poststroke central nervous system have been cited thoroughly in the literature; hence,
understanding what facilitates and limits this process could open the door to novel
treatment approaches.

1.6

Limitations to post-stroke central nervous system neuroplasticity
Opposite to trophic and growth-promoting factors are negative or inhibitory

factors, which also play a big part in orchestrating neuroplasticity. These include
components of CNS myelin (e.g. Nogo A, MAG, etc.), inhibitory extracellular matrix
(ECM) molecules that are often secreted by astrocytes, and receptors mediating growth
cone collapse, which are normally developmentally-regulated (Lee, Kim et al. 2004).
Perhaps the most salient of the inhibitory factors expressed in the injured CNS is a family
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of ECM molecules called chondroitin sulfate proteoglycans (CSPGs) (Eddleston and
Mucke 1993; Fawcett and Asher 1999; Silver and Miller 2004). They have been shown
to inhibit neurite outgrowth in many in intro and in vivo studies. When a sprouting
axon's growth cone comes in contact with CSPGs, protein tyrosine phosphate (PTP)
receptors are activated, and the resulting signaling pathways lead to growth cone collapse
(McKeon, Schreiber et al. 1991; Meiners, Powell et al. 1995; Davies, Fitch et al. 1997;
Zuo, Neubauer et al. 1998). CSPGs are composed of one of a variety of core proteins
covalently linked to chondroitin sulfate glycosaminoglycan chains, and are part of the
normal CNS extracellular matrix.
In addition to serving both structural and functional roles in the generally loosely
organized ECM throughout the CNS, CSPGs are also constituents of structures called
peri-neuronal nets: highly condensed matrix arrangements surrounding the cell bodies
and proximal dendrites of certain classes of neurons, which serve to stabilize synapses
and limit synaptic plasticity. The importance of peri-neuronal nets is seen especially in
the "critical period" of postnatal CNS development. This is a time when the CNS is
particularly plastic, in which appropriate experience leads to the organization of proper
neuronal networks. A lack of appropriate experiences may cause the formation of
incorrect neuronal connections (Wang and Fawcett 2012). The high degree of plasticity
and responsiveness to experience-based neuronal network formation in the critical period
has been well studied in the visual system. The end of the postnatal critical period is
marked by peri-neuronal net (PNN) deposition around neurons, which stabilizes
established connections in the CNS and limits plastic changes due to future experiences
(Wang and Fawcett 2012). Along with the establishment of peri-neuronal nets, then end
of critical period is also marked by a general upregulation of CSPGs in the CNS (Carulli,
Pizzorusso et al. 2010). After full CNS development, the disruption of PNNs can
reactivate plasticity and allow for activity-dependent changes to more easily modify
neuronal circuits (Wang and Fawcett 2012). However, despite their essentiality to the
proper development and function of the uninjured CNS, CSPGs can be detrimental to the
injured CNS (Galtrey and Fawcett 2007).
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The expression of both axonal growth-promoting and growth-inhibiting genes is
induced in specific waves and sequences in the post-stroke CNS (Carmichael,
Archibeque et al. 2005). The two main CNS regions that naturally experience tissue reorganization (due to ischemic damage and the balance between these positive and
negative factors) include a small area of cortex adjacent to the infarct area, as well as a
broader region including peri-infarct cortex and more distant CNS areas. As previously
discussed, due to reduced blood flow, the area closely bordering the infarct core
experiences oxidative DNA and protein damage, cell death, and reactive astrogliosis
(increase of astrocyte number and activation) (Katsman, Zheng et al. 2003; Carmichael,
Archibeque et al. 2005) A consequence of astrocyte activation in this region is a massive
increase in the production of axonal growth-inhibiting CSPGs. Interestingly enough, this
region simultaneously experiences increased expression of all of the growth-promoting
genes soon after injury as well. Despite this, axonal growth is limited in this area by the
negative factors present, which may serve to decrease aberrant connectivity or simply
interfere with the recovery process (Murphy and Corbett 2009).
The second area of interest (peri-infarct and more distant regions), however,
experiences reduced CSPG expression (which translates to diminished peri-neuronal
nets), as well as an increase in the expression of growth promoting genes. This
combination allows for increased axonal sprouting to occur in these areas, without
detrimental astrocyte activation and cell death (Carmichael 2003; Carmichael,
Archibeque et al. 2005). Unfortunately, this decrease in CSPG expression is transient.
Animal studies have shown that CSPG expression levels in these peri-infarct and remote
CNS areas gradually increase over a month's time to return to normal levels, essentially
closing the window of time for increased plasticity to occur (Carmichael, Archibeque et
al. 2005). Therefore, a possible strategy to improve recovery after stroke could be to
lessen growth-inhibiting factors, thereby altering the CNS microenvironment to better
promote beneficial neuroplasticity and axonal sprouting.
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1.7

Augmenting neuroplasticity to enhance recovery from CNS injury:
Examples from the literature
This strategy to improve recovery has been explored in animal models of a

number of different CNS injuries, and most commonly in spinal cord injury (SCI). For
example, Huang et al used myelin immunization in mice to stimulate the creation of
polyclonal antibodies to block myelin-associated axonal growth inhibitors. This resulted
in increased CNS axonal growth and regeneration in mice after SCI, and corresponding
improvements in hind leg function (Huang, McKerracher et al. 1999). In a similar
fashion, anti-Nogo antibodies, as well as peptide antagonists of Nogo-66 (which bind to
the Nogo receptor) have been used to augment axonal growth and the neuroplastic
response to improve functional recovery in rodent models of SCI (Schnell and Schwab
1990; Bregman, Kunkel-Bagden et al. 1995; Brosamle, Huber et al. 2000; GrandPre, Li et
al. 2002; Li and Strittmatter 2003). Related strategies have been implemented in studies
with animal models of stroke. For example, Papadapolous, Tsai et al used an antibody to
block the inhibitory protein Nogo-A in rats after middle cerebral artery occlusion (a
model of ischemic stroke), and observed increased axonal growth and functional recovery
in the treated animals (Papadopoulos, Tsai et al. 2002). Lee, Kim et al employed genetic
(hetero-and homozygous Nogo receptor knockouts) as well as pharmacologic methods to
diminish the Nogo-Nogo receptor system in rodents. Using rodent models of stroke, they
found in both cases that axonal plasticity and behavioural function were enhanced after
stroke when compared to control animals (Lee, Kim et al. 2004).
Perhaps most pertinent to this study is research that focuses on decreasing levels
of CSPGs in an attempt to improve neuronal plasticity and recovery after CNS injury.
One popular technique is to administer Chondroitinase ABC (ChABC): a bacterial
enzyme that catalyzes the degradation of CSPGs by cleaving off glycosaminoglycan
chains. Besides numerous in vitro studies demonstrating ChABC's ability to degrade
CSPGs and increase axonal plasticity, many proof of principle in vivo studies have been
done with ChABC as well (Fidler, Schuette et al. 1999; Schmalfeldt, Bandtlow et al.
2000). For example, although not a model of a common human CNS injury, treating
mice with ChABC at the lesion site after performing a unilateral nigrostriatal axotomy on
them was found to improve neuroplasticity. By diminishing inhibitory CSPG
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accumulation, the full development of a glial scar was prevented, which allowed axons to
extend across the lesion (Li, Homma et al. 2007). As with other strategies to improve
neuroplasticity, the use of ChABC has been examined in more complex CNS injuries,
like SCI. Bradbury, Moon et al treated spinal cord injured rats with intrathecal injections
of ChABC at the level of the lesion. This led to the degradation of CSPGs at the injury
site, and a consequent increase in neurite growth-associated proteins in injured neurons.
Tract tracing experiments also displayed regeneration of both ascending and descending
spinal axons. Electrophysiological tests highlighted the restoration of post-synaptic
activity below the lesion with ChABC treatment. All findings correlated with improved
locomotor and proprioceptive functional recovery in the ChABC treated rats,
emphasizing the therapeutic potential of targeting CSPGS in the injured CNS (Bradbury,
Moon et al. 2002).
One recent and particularly relevant study involves ChABC treatment in a rat
model of stroke (Soleman, Yip et al. 2012). Unlike other investigations of stroke
therapies in rodents that often target the lesioned area itself, Soleman et al concentrated
on more remote CNS areas for ChABC treatment. By administering ChABC into the
denervated side of the cervical spinal cord (relevant for forelimb function) 3 days poststroke, they hoped to induce localized plasticity of the spinal circuitry. Histological
analysis of the cervical spinal cord one week after ChABC injection showed unilateral
degradation of CSPGs, and reduced peri-neuronal net presence (by use of 2B6 and WFA
antibodies, respectively). Histological analysis of anterograde tract-tracing (by injecting
BDA into the contralesional motor cortex) in the cervical spinal cord showed an increase
in BDA-labeled collaterals sprouting on the deafferented side in ChABC-treated animals.
In accordance with increased neuroplasticity, they found that ChABC treatment also
significantly improved forelimb motor recovery by use of the staircase and cylinder tests,
as well as forelimb sensory recovery with a bilateral tactile stimulation test (Soleman,
Yip et al. 2012).
Thus, a number of studies have shown that a decrease in CSPGs creates a CNS
environment that encourages neurite-growth, reactivates plasticity, and promotes
functional recovery within the CNS after a number of injuries, including stroke.
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Although ChABC treatment may seem promising, the actual process of injecting the CNS
tissue is challenging and invasive, and treatment is limited to the areas surrounding the
injection sites. ChABC also has the major disadvantage of being unable to completely
digest the glycosaminoglycan chains from the core protein of CSPGs (Caterson, Christner
et al. 1985). This leaves carbohydrate "stubs" behind, which are less inhibitory to neurite
growth than the complete chains, but which can still reduce axon regeneration ability
(Lemons, Sandy et al. 2003). Therefore it would be beneficial to investigate methods to
prevent the increased production of CSPGs after CNS injury.
One such investigation by Grimpe, Silver et al used a ribozyme-based strategy to
target xylosyltransferase-I (XT-I), an enzyme involved in CSPG production that initiates
the synthesis of chondroitin sulfate side chains. By decreasing XT-I messenger RNA,
they were able to show a strong reduction in the levels of inhibitory GAG chains in the
rodent lesion penumbra after SCI, which led to the regeneration of axons well beyond the
core lesion (Grimpe and Silver 2004). However, like with ChABC, the delivery of this
ribozyme is also limited to the areas surrounding the injection site. Therefore, it would
be beneficial to investigate how decreasing CSPGs in a more global manner in the CNS
could affect recovery after CNS injury as well.

1.8

The role of the transcription factor SOX9 in the post-stroke CNS
To target CSPGs on a more global CNS basis, it is important to understand the

process of CSPG production. Synthesis of the chondroitin sulfate side chains is initiated
by adding xylose to a serine component of the core protein. This is the rate-limiting step
in the production of chondroitin sulfate side chains, and is completed by the enzyme
xylosyltransferase (XT, as mentioned previously). XT exists in two isoforms that are
encoded by two different genes, XT-I and XT-II (Schwartz 1977; Kearns, Campbell et al.
1991; Gotting, Kuhn et al. 2000). Next, these side chains are sulfated by either
chondroitin 4-sulfotransferase (C4ST) (Yamauchi, Mita et al. 2000), or chondroitin 6sulfotransferase (C6ST), (Fukuta, Uchimura et al. 1995). However, C4ST is the main
type present in astrocytes (Gallo and Bertolotto 1990). Our lab has identified the
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transcription factor SOX9 as being responsible for upregulating the expression of XT-I,
XT-II, and C4ST with bioinformatics and in vitro studies (Gris, Tighe et al. 2007).
Unpublished chromatin immunoprecipitation experimental data confirms that the
regulation is likely direct. This discovery led our lab to develop the hypothesis that
SOX9 inhibition after a CNS injury would lead to decreased CSPG production, and
consequently, a microenvironment that better promotes nerve growth and neurological
recovery.
Sox9 is part of a family of transcription factors composed of 20 different genes,
all with a high mobility group (HMG-box) DNA binding domain of similar sequence
homology to that of the Y chromosome-encoded testis determining factor SRY (Moniot,
Declosmenil et al. 2009). Sox9 plays a critical role in sex determination, and in nervous
system development. Since conventional Sox9 knockout mice do not survive perinatally
(Bi, Huang et al. 2001), it was necessary to use a conditional Sox9 knockout line of mice
to study the role of SOX9 in recovery from CNS injury (Outlined in 2.1 of Methods and
Materials).
We have studied the role of SOX9 after spinal cord injury for several years now
by crossing mice obtained from Dr. Andreas Schedl (mice with floxed Sox9 alleles) with
mice obtained from Jackson Laboratories (mice with Cre-recombinase fused to the
mutated ligand binding domain of the human estrogen receptor). The resulting mouse
line containing both floxed Sox9 and Cre recombinase allowed us to examine the
molecular, cellular, and neurological responses to spinal cord injury in which SOX9
expression levels were reduced in all cell types. It was confirmed that these mice did, in
fact, exhibit significantly lower levels of Sox9 mRNA and protein with real-time PCR
and western blot analyses (McKillop, Dragan et al. 2013). After inducing a 70 kdyne
contusion spinal cord injury in the mice, Sox9 knockout mice experienced improved
recovery in hind limb functioned as measured by the Basso mouse scale (BMS), which
examines ankle movement and walking ability. Using rodent activity boxes, it was found
that Sox9 knockout mice locomoted to a greater extent than the control mice after injury.
Improvements in functional recovery were associated with reduced astrocytic activation
as well as lower CSPG levels at the lesion site in Sox9 knockout animals compared to
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control animals (McKillop, Dragan et al. 2013). Success with improving function after
SCI in mice led us to consider applying Sox9 ablation in other models of CNS injury.
Hence, similar studies to examine the effects of Sox9 ablation in a mouse model of stroke
were carried out.

1.9

Preliminary work on Sox9 ablation in a mouse model of stroke
Prior to this study, Dr. Kathy Xu of the Brown lab had done preliminary work

characterizing the effects of conditional Sox9 ablation in a mouse model of stroke. Since
ischemic stroke in human patients usually results from a thrombotic or embolic occlusion
in a major cerebral artery, and most often the middle cerebral artery (MCA), a commonly
used method to reproduce stroke in animals is to occlude temporarily the MCA (Durukan
and Tatlisumak 2007; Liu and McCullough 2011) . As such, MCAO (middle cerebral
artery occlusion) is the stroke model used in this study. The following preliminary
findings are currently unpublished. To begin, all animals underwent surgical intra-arterial
suture occlusion of the middle cerebral artery through the internal carotid artery. The
suture was removed 30 minutes later, which allowed reperfusion of the affected area.
This injury model causes rapid infarction of the striatum, and delayed infarction in the
overlying cortex (Carmichael 2005). Longer occlusion times can lead to widespread
malignant infarction in the rodent brain, which does not model the most common cases of
human stroke (Carmichael 2005).
To ensure that the size and area of the infarcts produced after MCAO were equal
among Sox9 knockout and control animals, 2,3,5-triphenyltetrazolium chloride (TTC)
staining was performed on the animals' brains 24 hours after injury. The infarct volumes
were found to be statistically equivalent between groups, indicating that equal injuries
were being produced after the 30 minute MCAO. After ensuring an equal injury,
histological, western blot, and densitometric analyses confirmed that SOX9 protein levels
were significantly reduced in the brains of the Sox9 KO animals when compared to
controls two weeks after MCAO (more pronounced on the side of the brain ipsilateral to
injury). Next, it was logical to examine if this reduction in SOX9 affected CSPG levels
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in the injured central nervous systems of both sets of mice. CSPG levels of the diffuse
ECM, as well as levels of the CSPG-rich highly condensed matrix structures called perineuronal nets were examined two weeks after MCAO (using CS56, and WFA antibodies,
respectively). Histological, western blot and densitometric analyses of CS56 two weeks
post-MCAO showed a significant reduction of diffuse extra-cellular matrix CSPGs in the
striata of Sox9 KO mice compared to controls (again, even more profoundly on the side
ipsilateral to injury).
Levels of synapse-stabilizing PNNs were examined at more remote CNS areas
that are particularly relevant to motor function in the mouse: the red nucleus (a midbrain
neuronal cluster that plays an important role in locomotion and skilled limb movements)
(Muir and Whishaw 2000), and the ventral horn of the cervical spinal cord (where motor
neurons controlling forelimb functions receive input from the brain) (Lemon 2008). In
both cases, histological and immunoreactivity imaging analyses confirmed that PNN
levels (examined with wisteria floribunda agglutin or WFA) were significantly lower on
the deafferented sides of both the red nucleus and cervical spinal cord of the Sox9
knockout mice compared to controls two weeks after MCAO. Altogether, these data
show that our tamoxifen-inducible conditional Sox9 knockout model works as
hypothesized, in that SOX9 and CSPG levels are significantly reduced in the CNS after
stroke. This study focuses on answering important follow-up questions to these
preliminary finding: How does the ablation of Sox9 and the consequent reduction in
CSPG and PNN levels in the CNS affect neuroplasticity and functional recovery after
stroke?

1.10

Background Summary and Rationale
Ischemic stroke is a detrimental vascular occurrence in which blood flow to the

brain is interrupted. It is a leading cause of death and disability worldwide, and requires
further investigation into better avenues for treatment. Recovery can occur after a stroke,
but is often limited, and will plateau after about 6 months. Any recovery that does occur
is generally attributed to neuroplasticity: the central nervous system's ability to
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reconfigure in an attempt to take over for lost and damaged functions. Something that
limits this post-stroke neuroplasticity is the expression of extracellular matrix molecules
called chondroitin sulfate proteoglycans (CSPGs). CSPGs can act as physical and
molecular barriers to neuronal growth, and are also a component of highly condensed
matrix structures called peri-neuronal nets, which stabilize synapses and limits
neuroplasticity. Our research group has identified the transcription factor SOX9 as
responsible for upregulating the expression of CSPGs in the injured brain. We
hypothesized that by conditionally knocking out the gene Sox9 in mice, the expression of
CSPGs would decrease. This would create a CNS microenvironment that is more
conducive to neuroplastic events, and in turn, lead to increased neurological recovery
after stroke.
To summarize:
•

Normal recovery after stroke, however limited, is generally due to neuroplasticity.

•

CSPGs, the expression of which is upregulated after a CNS injury like stroke,
inhibit neuroplasticity.

•

Work done in our lab has shown that SOX9 is a transcription factor that increases
CSPG expression in the injured CNS. By conditionally knocking out Sox9, we
can decrease CSPG and peri-neuronal net levels in the mouse CNS.

•

The purpose of this study is to investigate if a decrease in SOX9 and consequently
CSPG expression will lead to increased neuroplasticity, and in turn, improved
functional recovery after stroke.

1.11

Hypothesis
I hypothesize that conditional ablation of Sox9 in mice will lead to increased

functional recovery after middle cerebral artery occlusion (a rodent model of
stroke), and will be accompanied by increased neuroplasticity when compared to
control mice.
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1.12

Objectives

The objectives of this study are to:
1) Investigate the effects of conditional Sox9 ablation in mice on neurological
and functional recovery after MCAO compared to control mice (by use of corner,
cylinder, and grip strength tests).
2) Evaluate neuroplasticity after MCAO in mice, and compare between Sox9ablated animals and controls (by use of corticorubral and corticospinal tract
tracing, as well as immunohistological examination of synaptic marker
expression levels).

1.13

Overview of experimental plan
Objectives 1 and 2 are approached using the same experimental timeline. Using a

Cre-loxP strategy, both Sox9flox/flox;Cre and Sox9flox/flox mice are administered tamoxifen to
induce Sox9 ablation in the Sox9flox/flox;Cre mice. This Cre-LoxP strategy is outlined in
Figure 1. After tamoxifen administration, a one-week washout period occurs to allow
recombination to occur, and for tamoxifen to leave the system. During this week, preinjury behavioural test data are acquired. Thereafter, both sets of mice undergo left-sided
MCAO surgery. A small number of animals of both genotypes are subjected to sham
surgeries, to serve as another type of control. Data for Objective 1 are obtained by doing
behavioural testing with the mice (corner, cylinder, and grip strength tests) for the
subsequent 4 weeks, and comparing results between Sox9-ablated animals and controls.
Next, a tract tracing experiment begins in the same animals by injecting BDA into the
right (unaffected) motor cortex. Two weeks later, the animals are perfused and the brain
and spinal cord tissues are sectioned to use for histological analysis.
For Objective 2, neuroplasticity is evaluated at two areas of the central nervous
system that are important for the motor functions analyzed in the behavioural tests: the
red nucleus within the brain, and the cervical enlargement of the spinal cord. To evaluate
structural neuroplasticity, BDA is injected into the right motor cortex (uninjured side)
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and BDA-labeled fibers on both sides of the red nucleus and cervical spinal cord are
counted. The number of BDA-labeled fibers on the deafferented side of each CNS
location is normalized to the number of fibers on the opposite side (to control for labeling
efficiency), and results are compared between Sox9-ablated and control animals. To
examine putative synaptic neuroplasticity, immunohistochemistry is used to stain for
glutamatergic synaptic markers (vesicular glutamate transporter 1 and 2, or VGLUT1 and
VGLUT2). On the deafferented side of each area (left-sided red nucleus and right-sided
cervical spinal cord), signal over background levels of VGLUT staining is calculated, (as
area/area or volume/volume) and compared between Sox9-ablated and control animals.
Results for sham animals are also assessed. To add a more acute post-injury time point to
the red nucleus VGLUT1 and VGLUT2 data, brain sections from a previous experiment
in which both Sox9flox/flox;Cre and Sox9flox/flox animals were perfused 48 hours after MCAO
are also used.
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Figure 1: A schematic representation of the Cre-loxP strategy to knockout the Sox9
gene. In Sox9flox/flox;Cre mice, the administration of tamoxifen (TM) releases heat-shock
protein 90 from the Cre-ER protein complex, allowing it to enter the nucleus of the cell.
Exons 2 and 3 of the Sox9 gene between the loxP sites are excised, effectively preventing
SOX9 expression. Tamoxifen is also administered to the Sox9flox/flox mice; however, there
is no Cre-ER present within the cells to excise the Sox9 gene, so SOX9 expression is
normal.
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Cellular mechanism for conditional Sox9 knockout
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Chapter 2:

Materials and Methods
2.1

Animals
Conventional Sox9 knockout mouse embryos (homozygous and heterozygous,

Sox9-/- and Sox9+/-, respectively) are not viable (Bi, Huang et al. 2001). As such, a
tamoxifen-inducible conditional Sox9 knockout strategy was used to allow the mice to
progress through development with normal SOX9 activity. We bred a mouse strain
(obtained from Dr. Andreas Schedl) carrying floxed Sox9 alleles (exons 2 and 3 of Sox9
surrounded by loxP sites) (Akiyama, Chaboissier et al. 2002) with a transgenic mouse
line ubiquitously expressing Cre recombinase fused to the mutated ligand binding domain
of the human estrogen receptor (ER) under the control of a chimeric cytomeglovirus
(CMV) immediate-early enhancer/chicken ß-actin promotor (B6.Cg-Tg(CAG-Cre /
Esr1)5Amc / J)) (Jackson Laboratories, Bar Harbor, ME). The two populations of
resulting offspring served as tamoxifen-inducible Sox9 knockout mice
(Sox9flox/flox;CAGGCreER, here after referred to as Sox9flox/flox;Cre), and control mice with
normal expression levels of Sox9 (Sox9flox/flox). Polymerase chain reaction analysis was
used to genotype the animals using the following primers:
Sox9flox allele: 5’-ACACAGCATAGGCTACCTG-3’ and
5’-GGTAATGAGTCATACACAGTAC-3’.
Sox9wildtype allele: 5’ GGGGCTTGTCTCCTTCAGAG-3’ and
5’-TGGTAATGAGTCATACACAGTAC-3’.
Sox9knock-out allele: 5’-GTCAAGCGACCCATG-3’ and
5’-TGGTAATGAGTCATACACAGTAC-3’.
Cre+ allele: 5’-CAATTTACTGACCGTACAC-3’ and
5’-AGCTGGCCCAAATGTTGCTG-3’.
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2.2

Tamoxifen administration
Both Sox9flox/flox;Cre and Sox9flox/flox mice were administered tamoxifen (Sigma

Aldrich, St. Louis, MO) by oral gavage at a dose of 3 mg/20 g mouse. The drug was
given once a day for 7 days, followed by a 7 day period without treatment (to allow for
Cre-mediated recombination and tamoxifen clearance to occur before MCAO surgery).

2.3

Induction of focal cerebral ischemia
All protocols for these experiments were approved by the University of Western

Ontario Animal Care Committee in accordance with the policies established in the Guide
to Care and Use of Experimental Animals prepared by the Canadian Council on Animal
Care. Male mice weighing 25-30g were allowed free access to food and water. One week
after the last dose of tamoxifen was administered, mice were anesthetized with 4%
isofluorane and maintained at 1.5% isofluorane and 30% O2. Body temperature was
maintained using a heating pad. Cerebral ischemia was induced using an intraluminal
filament technique (protocol outlined by (Rupadevi, Parasuraman et al. 2011). A midline
neck incision was made and left common and external carotid arteries were isolated and
ligated. A 5-0 nylon monofilament coated with 0.1% poly-l-lysine was introduced
through a small incision into the common carotid artery and advanced to the carotid
bifurcation for middle cerebral artery occlusion (MCAO). Reperfusion was initiated 30
minutes later by monofilament withdrawal. The mortality rate for these mice was
approximately 15%. In sham-operated animals, the monofilament was placed into the
MCA and withdrawn immediately. Animals were administered Baytril (25 mg/kg,
Bayer, Toronto, Ontario, Canada) and bupenorphrine (0.01 mg/kg, Schering-Plough,
Hertfordshire, UK) subcutaneously after MCAO, and then twice daily for three days after
the surgery. If mice showed no signs of functional deficits (circling, etc.) after the 30
minute MCAO, they were not included in the study.
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2.4

Measurement of local cerebral blood flow using Laser Doppler
Flowmetry
Laser Doppler Flowmetry was used to measure cerebral blood flow and verify

that MCAO had occurred. This test was done on a separate set of animals to ensure the
reproducibility of the MCAO (n=3). The OXYLAB flowmeter is equipped with a smallcaliber probe of 0.7mm diameter (Oxford Optronix, Oxford, UK). The mice were placed
in a sterotaxic frame with a mouse holder, and anesthetized with 4% isoflurane and
maintained at 1.5% isoflurane and 30% O2. Body temperature was monitored and
maintained using a heating pad. A midline incision was made and a burr-hole (0.7 mm in
diameter) was drilled 1mm posterior and 4mm lateral to the sagittal suture on the left side
of the skull. The probe was held in a micromanipulator and was stereotaxically advanced
to gently touch the dura covering the ischemic core region. Warm saline (37°C) was
slowly rinsed around the probe and maintained a clear medium between the probe and the
dura during the measurement. Stable baseline laser doppler flowmetry readings were
obtained prior to MCAO surgery. The changes of regional CBF were recorded 5 minutes
into the occlusion of the middle cerebral artery. A sharp drop over 85% (85.8±2.5%) of
baseline was noted, which remained stable throughout the 30 minute occlusion.

2.5

Behaviour: functional neurological tests

2.5.1 Corner test
Initially designed by Schallert et al (1982) for rats and later adapted by Zhang et
al (2002) to mice, the corner test is used to detect sensori-motor and postural
asymmetries The apparatus consists of a corner made by two vertical boards
(30 × 20 × 1 cm3) attached on one side with an angle of 30°. A small opening between
the boards encourages the mouse to go into the corner. Each mouse is placed at the entry
of the corner facing into it. When the mouse reaches the wedge of the corner, both sides
of the body (vibrissae, skin) are stimulated simultaneously. Then, the mouse typically
rears, and turns either to the right or to the left to exit the corner. Corner tests were
carried out before injury, as well as 2 days afterward, and once per week for four weeks
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following MCAO surgery. During each test, the mice were tested ten times (about 2
minutes per animal), and the chosen sides were noted. In case of ventral turning (i.e.
when the mouse turned without rearing), the trial was not taken into account but repeated
at the end of the session.

2.5.2 Cylinder test
The cylinder test was initially used in rats and later adapted for use in mice to
assess forelimb use asymmetry (Schallert, Fleming et al. 2000; Li, Blizzard et al. 2004).
The mice are placed in a transparent cylinder (9 cm in diameter and 15 cm in height) and
videotaped during the test. A mirror is placed behind the cylinder with an angle to enable
the observer to record forelimb movements when the mouse is turned away from the
camera. After the mouse is put into the cylinder, forelimb use of the first contact against
the wall after rearing, and during lateral exploration, is recorded by the following criteria:
(1) The first forelimb to contact the wall during a full rear is recorded as an independent
wall placement for that limb. (2) Simultaneous use of both the left and right forelimb by
contacting the wall of the cylinder during a full rear and for lateral movements along the
wall is recorded as a ‘‘both’’ movement. (3) After the first forelimb (for example right
forelimb) contacts the wall and then the other forelimb is placed on the wall, but the right
forelimb is not removed from the wall, a ‘‘right forelimb independent’’ movement and a
‘‘both’’ movement are recorded. A minimum of 20 movements are recorded during the
three minute test. If the mouse did not complete 20 forelimb placements, a second trial
was performed later that day. If 20 forelimb placements could not be recorded again, the
animal was not included in the study.
Cylinder tests occurred three days after injury, as well as once a week for four
weeks following MCAO surgery. The asymmetry score for each test day is calculated as:
(non-impaired forelimb movement - impaired forelimb movement) / (non-impaired
forelimb movement + impaired forelimb movement + both movement) as previously
described in the rat (Schallert, Fleming et al. 2000). This test evaluates forelimb use
asymmetry for weight shifting during vertical exploration and provides high inter-rater
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reliability, even with inexperienced raters. Occasionally, mice with large deficits did not
move frequently enough to obtain an adequate number of vertical movements.

2.5.3 Grip strength test
The grip strength test was performed using a Grip Strength Meter (Columbus
Instrument, Columbus, OH). It employs a triangular steel wire that the animal
instinctively grasps. When pulled by the tail, the animal exerts force on the steel wire
(Kilic, ElAli et al. 2010). The left forepaw is wrapped with adhesive tape so that grip
strength in the right forepaw (affected by the left-sided MCAO) could be evaluated. Grip
strength was measured five times in each test, and the highest score was recorded. Grip
strength was measured before the MCAO surgery, and then once a week afterwards for
four weeks. From these data, percentage values for each week post-MCAO measurement
compared to the initial pre-MCAO recording were calculated. If mice consistently failed
to grab the steel wire for the proper acquisition of a grip-strength reading, they were not
included in the study.

2.6

Delivery of biotinylated dextran amines (BDA)
The protocol for anterograde axonal tract tracing in rats had been established

previously (O'Neill and Clemens 2001). Here, we adopted this method to mice. Four
weeks after MCAO, the mice were placed in a sterotaxic frame with a mouse holder, and
anesthetized with 4% isoflurane and maintained at 1.5% isoflurane and 30% O2. Body
temperature was monitored and maintained at 36ºC using a heating pad and rectal
thermometer. A small piece of skull (1.5mm in diameter) overlaying the right motor
cortex was removed. A total volume of 1.6µl 10% BDA (10,000 MW, Molecular Probes)
was administered to each animal, using a Hamilton microsyringe, paired with a 33G
needle. Four equal injections were administered to cover the forelimb representation area
in the motor cortex, contralateral to the stroke, located at 0.5mm anterior and posterior to
the bregma; 1.5mm and 2.5mm lateral to the sagittal suture, respectively, at a depth of
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0.5mm. The needle was kept in place after injection for at least 2 minutes to avoid the
leakage from the injection site. After all four injections, the incision was sutured.
Animals were administered Baytril (25 mg/kg, Bayer, Toronto, Ontario, Canada) and
bupenorphrine (0.01 mg/kg, Schering-Plough, Hertfordshire, UK) subcutaneously after
the surgery, and then twice daily for three days.

2.7

Perfusions
Three weeks post-BDA injection, the mice were deeply anesthetized with 100

mg/kg ketamine: 5 mg/kg xylazine, and transcardially perfused with ice cold saline
solution, followed by 4% paraformaldehyde (4% PFA in 0.1 M phosphate buffer at pH
7.4). The experimental timeline is shown in Figure 2. Brains and spinal cords were
dissected, post-fixed in 4% PFA for 1 hour, and then cryoprotected in 20% sucrose at 4ºC
overnight. Brains and spinal cords were dissected and embedded in Tissue Tek O.C.T.
Compound (Sakura Finetek USA Inc., Torrance, CA), frozen over dry ice and stored at 80ºC. The brains were cross sectioned at 10µm using a cryostat, and serially thawmounted on SuperfrostTM glass slides (Fisher Scientific Company, Ottawa, Canada).
Collected brain sections alternated on 10 slides with 5 sections per slide so each section
per slide was separated by 100µm. Cervical spinal cords were cross sectioned at 10µm
using a cryostat, and serially thaw-mounted on SuperfrostTM glass slides (Fisher
Scientific Company, Ottawa, Canada) as well. Collected cervical spinal cord transverse
sections alternated on 10 slides with 10 sections per slide so that each section per slide
was separated by 100µm.
To add a more acute post-injury time point to the red nucleus glutamatergic input
data (VGLUT1 and VGLUT2, as described in section 2.9) brain sections from
Sox9flox/flox;Cre and Sox9flox/flox animals that were perfused 48 hours after MCAO were also
used. The experimental timeline for these animals is also shown in Figure 2. Brains
were dissected, sectioned and serially thaw-mounted in the manner described above.
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Figure 2: Experimental timelines for both experiments discussed in this thesis
A) Timeline for the MCAO experiment, with behavioural analyses and an anterograde
neuronal tracer injection into the contralesional motor cortex. The two groups of mice used
include the ubiquitous Sox9 knockout mice (Sox9flox/flox;Cre-ER) and their littermate
controls (Sox9flox/flox).
B) Timeline for the MCAO experiment in which both the ubiquitous Sox9 knockout mice
(Sox9flox/flox;Cre-ER) and their littermate controls (Sox9flox/flox) were sacrificed 48 hours
after MCAO. The brain tissue was used to contribute to the VGLUT quantification data.
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A

Timeline for MCAO experiment, including behavioural analyses and
BDA injection in control and Sox9 knockout mice

B

Timeline for past MCAO experiment with 48 hour post-surgery
sacrifice in control and Sox9 knockout mice
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2.8

Immunohistochemistry and analysis for biotinylated dextran amines

2.8.1 Immunohistochemistry for biotinylated dextran amines (BDA)
Brain and cervical spinal cord sections were washed three times for 10 minutes in
TBS, and then incubated with 0.3% hydrogen peroxide in methanol for 30 minutes to
quench the endogenous peroxidase activity. After three more TBS washes, the sections
were incubated in blocking solution (5% milk, 1% bovine serum albumin, and 0.3%
Triton X-100 in TBS) for 1 hour. Another set of TBS washes followed, and then the
sections were incubated with avidin-biotin-peroxidase complex (ABC Elite; Vector
Laboratories, Burlingame, CA, USA) in TBS with 0.5% Triton X-100 for 2 hours. After
a final set of TBS washes, staining was revealed with a 3,3'-diaminobenxidine reaction
(DAB, Invitrogen, Carlsbad, CA). Sections were then washed in dH20, dehydrated, and
protected with a coverslip using XYL mounting medium (Fisher Scientific Company,
Ottawa, Canada).

2.8.2 Analysis of corticorubral projections
Three coronal sections at the level of the parvocellular red nucleus (at least 100
µm apart) were examined to evaluate the corticorubral projections. Images of each
section were captured with a 10X and a 20X objective lens (Olympus BX50). First, the
labeled fibers from all three sections in the contralesional hemisphere (ipsilateral to BDA
injection) projecting to the red nucleus were counted.

For each section, the fibers

present on the ipsilesional side (contralateral to BDA injection) were quantified and
normalized to the total number of the labeled fibers on the contralesional side (to control
for labeling efficiency). Fiber numbers were quantified by two separate raters (myself
and Dr. Kathy Xu), and then averaged to obtain the final fiber counts. Fibers had to have
a minimum length of 3µm to be counted. Only the animals that had more than 100
labeled fibers on the contralesional side using the 10X objective were included to ensure
adequate labeling efficiency.
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2.8.3 Analysis of corticospinal projections
Eight transverse spinal cord sections at the level of cervical enlargement (at least
100 µm apart) were examined to evaluate the corticospinal projections. Images of each
section were captured with a 10X and a 20X objective lens (Olympus BX50). To begin,
in all eight cervical spinal cord sections, the labeled fibers in the grey matter on the
contralesional side (ipsilateral to BDA injection) were counted. For each section, the
fibers present within the grey matter of the contralesional side of the cervical spinal cord
(ipislateral to BDA injection) were quantified and normalized to the total number of the
labeled fibers on the ipsilesional side (to control for labeling efficiency). Fiber numbers
were quantified by two separate raters (myself and Dr. Kathy Xu), and then averaged to
obtain the final fiber counts. Fibers had to have a minimum length of 3µm to be counted.
Only the animals that had more than 100 labeled fibers on the ipsilesional side using the
10X objective were included to ensure adequate labeling efficiency.

2.9

Immunohistochemistry and analysis for glutamatergic input markers
VGLUT1 and VGLUT2 at the level of the ipsilesional red nucleus

2.9.1 Immunohistochemistry for VGLUT1, VGLUT2 and SMI-32
SMI-32 is an antibody for a non-phosphorylated epitope in neurofilament heavy
polypeptide, which is found within the neuronal cell bodies, dendrites, and some thick
axons of rubrospinal cells in the red nucleus (Liang, Paxinos et al. 2012). This antibody
was used to identify the location of the red nucleus. VGLUT1 and VGLUT2 antibodies
were used to stain for vesicular glutamate transporter 1, and 2, respectively (markers of
glutamate transporters in the membranes of synaptic vesicles). VGLUT1 is the major
glutamate transporter expressed in layer V motor cortex neurons (including corticorubral)
, while VGLUT2 is the major glutamate transporter in cerebellar and thalamic projections
to the red nucleus (Allen Brain Atlas - VGlut2 in mouse brain; Allen Brain Atlas VGlut1 in mouse brain; Naus, Flumerfelt et al. 1986; Roger and Cadusseau 1987;
Arnault, Ebrahimi-Gaillard et al. 1994; Varoqui, Schafer et al. 2002; Fink, Englund et al.
2006; Barroso-Chinea, Castle et al. 2007).
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Brain sections from Sox9flox/flox;Cre and Sox9flox/flox mice were incubated with
blocking solution (5% goat serum in PBS, with 0.1% Triton X-100) at room temperature
for 2 hours, and then incubated with primary antibodies diluted in blocking solution at
4ºC overnight. The primary antibodies used were: mouse anti-SMI-32 (1:1000,
Covance, catalogue # SMI-32R), along with either rabbit anti-VGLUT1 (1:500, Synaptic
Systems, catalogue # 135 302) or rabbit anti-VGLUT2 (1:500, Synaptic Systems,
catalogue # 135 402). Sections were washed three times for 10 minutes, after which
immunofluorescent labeling was performed using the following secondary antibodies (for
one hour at room temperature): Alexa Fluor 488 goat anti-mouse IgG (1:500, Life
Technologies, catalogue # A-11029), and Alexa Fluor 647 goat anti-rabbit (1:1000, Life
Technologies, catalogue # A-21244). After washing three times in PBS for at least 30
minutes, the sections were protected with a coverslip using ProLong Gold Anti-Fade
mounting medium with DAPI (Life Technologies, catalogue # P36935).

2.9.2 Analysis of glutamatergic input markers VGLUT1 and VGLUT2 at the
level of the ipsilesional red nucleus
Three coronal sections at the level of the parvocellular red nucleus (at least 100
µm apart) were examined to evaluate levels of presynaptic glutamatergic markers within
the ipsilesional red nucleus (three sections each for both VGLUT1 and VGLUT2). Zstacks 2 µm in thickness (composed of 10 sections at a thickness of 0.2µm) were
captured with a 40X objective lens with a spinning disk confocal microscope and
Volocity software (CSU10, with an Olympus IXS1). Images were deconvoluted with
Autoquant X software (Media Cybernetics Inc., Rockville, MD, USA). Using Imaris
software (Bitplane AG, Zurich, Switzerland) VGLUT1 and VGLUT2 signal greater than
background within the red nucleus was identified and quantified (as volume of
immunoreactivity/volume of red nucleus section). Average VGLUT1 and VGLUT2
immunoreactivity levels (volume/volume) were determined for each animal.
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2.10

Immunohistochemistry and analysis for glutamatergic input marker
VGLUT1 at the level of the contralesional cervical spinal cord

2.10.1 Immunohistochemistry for VGLUT1 and NeuN
Vesicular glutamate transporter 1 (VGLUT1) is the major glutamate transporter
present in corticospinal cells (Varoqui, Schafer et al. 2002), whereas NeuN serves as a
general neuronal marker (a neuronal specific nuclear protein in vertebrates) to aid in
locating the ventral horn (Varoqui, Schafer et al. 2002). Cervical spinal cord sections
from Sox9flox/flox;Cre and Sox9flox/flox mice were incubated with blocking solution (5%
goat serum in PBS, with 0.1% Triton X-100) at room temperature for 2 hours, and then
incubated with primary antibodies diluted in blocking solution at 4ºC overnight. The
primary antibodies used were: mouse anti-NeuN (1:200, Millipore, catalogue #
MAB377), and rabbit anti-VGLUT1 (1:500, Synaptic Systems, catalogue # 135 302).
Sections were washed three times for 10 minutes, after which immunofluorescent
labeling was performed using the following secondary antibodies (for one hour at room
temperature): Alexa Fluor 488 goat anti-mouse IgG (1:500, Life Technologies, catalogue
# A-11029), and Alexa Fluor 594 goat anti-rabbit (1:1000, Life Technologies, catalogue
# A-11072). After washing three times in PBS for at least 30 minutes each, the sections
were protected with a coverslip using ProLong Gold Anti-Fade mounting medium with
DAPI (Life Technologies, catalogue # P36935).

2.10.2 Analysis of glutamatergic input marker VGLUT1at the level of the
contralesional cervical spinal cord
Eight transverse spinal cord sections at the level of the cervical enlargement (at
least 100µm apart) were examined to evaluate levels of VGLUT1 within the
contralesional cervical spinal cord ventral horns. Images of each section were captured
with a 10X objective lens (Olympus BX50). Using Image Pro Plus software, VGLUT1
signal greater than background within the ventral horns was identified and quantified (as
area of immunoreactivity/area of ventral horn section). An average VGLUT1
immunoreactivity level (area/area) was determined for each animal.
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2.11

Immunohistochemistry and fluorescent microscopy for BDA-labeled
fibers at the level of the ipsilesional red nucleus

2.11.1 Immunohistochemistry for BDA-labeled fibers at the level of the
ipsilesional red nucleus
Brain sections from Sox9flox/flox;Cre mice were incubated with blocking solution
(4% goat serum, 1% bovine serum albumin in PBS, with 0.05% Triton X-100) at room
temperature for 2 hours, and then incubated with the primary antibody mouse anti-SMI32 (1:1000, Covance, catalogue # SMI-32R) diluted in blocking solution at 4ºC
overnight. Sections were washed three times for 10 minutes, after which
immunofluorescent labeling was performed using the following secondary antibodies (for
one hour at room temperature): Alexa Fluor 488 goat anti-mouse IgG (1:500, Invitrogen,
catalogue # A11029), and Streptavidin Alexa Fluor 594 conjugate (1:1000, Invitrogen,
catalogue # S-11227). After washing three times in PBS for 10 minutes, 0.5% sudan
black in 70% ethanol was applied to the sections for 90 seconds. The sections were
rinsed three times for one minute in 70% ethanol, then washed twice for 5 minutes in
PBS, and finally protected with a coverslip using ProLong Gold Anti-Fade mounting
medium with DAPI (Life Technologies, catalogue # P36935).

2.11.2

Microscopy for BDA- labeled fibers at the level of the ipsilesional
red nucleus
Coronal sections at the level of the parvocellular red nucleus within

Sox9flox/flox;Cre mice (6 weeks post-MCAO) were examined. The objective was to
capture a high quality photomicrograph of a BDA-labeled fiber extending to an SMI-32
positive cell in the ipsilesional red nucleus (contralateral to the BDA injection). A 2 µm
Z-stack (composed of 10 sections at a thickness of 0.2 µm) was captured with a 60X
objective lens on a confocal microscope (Zeiss LSM 510 Meta).
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2.12

Statistics
Data are presented as the mean ± standard error of the mean (SEM). Behavioural

test data were analyzed with two-way repeated measures analysis of variance (ANOVA)
tests to detect significant effects of genotype and/or time, as well as any interactions. If a
significant genotype by time interaction effect was noticed (p≤ 0.05), a post-hoc test
(Bonferroni) was carried out. Results obtained from the BDA tract tracing experiments
were analyzed with Student's t-tests. In both the corticorubral and corticospinal tract
analyses, significance was noted when p<0.05. Vesicular glutamate transporter
immunohistochemistry results were analyzed with One-way ANOVA tests. If the means
were determined to be statistically different, a Newman-Keuls post-hoc test was carried
out to detect significant differences between both genotypes at all time points (p<0.05).
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Chapter 3:

Results:
3.1

Effects of Sox9 ablation on functional recovery after MCAO
To determine if conditionally knocking out Sox9 in mice had an effect on

functional recovery after MCAO, three separate behavioural tests were used for
assessment. After one week of tamoxifen administration, a one week washout period to
allow recombination to take place occurred, during which both Sox9flox/flox;Cre and
Sox9flox/flox mice underwent pre-testing for sensori-motor function to determine baseline
measurements. After being subjected to a 30-minute MCAO injury, neurological
recovery of the mice was measured over the subsequent four weeks using the corner,
cylinder, and grip strength tests.

3.1.1 Corner test: Sensori-motor recovery after MCAO was improved in
Sox9 knockout mice compared to controls
The corner test was used to detect sensori-motor and postural asymmetries.
Before MCAO surgery, control and Sox9 KO animals made approximately the same
number of turns on either side (4.83 ± 0.37 and 4.93 ± 0.195 left turns, respectively).
After receiving a left-sided MCAO, all animals displayed an increase in left turns by two
days post-surgery. Considerable sensori-motor recovery was seen as early as one week
after injury in the Sox9 KO mice, and by two weeks afterward, they had returned to preinjury behaviour in which no side preference for turning was noted (7.25 ± 0.494 left
turns for controls versus 5 ± 0.277 left turns for Sox9 KOs). A two-way repeated
measures ANOVA test revealed significant effects of genotype and time (p<0.0001), as
well as a genotype by time interaction (p=0.0024). Bonferroni post-hoc analyses showed
that Sox9 KO mice experienced significantly improved sensori-motor functional recovery
compared to controls on post-MCAO weeks one through four (p<0.05).
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Figure 3: Sox9 KO mice demonstrate improved recovery of sensori-motor function
following MCAO as observed in the corner test. All animals subjected to the left-sided
MCAO showed an increase in left turns by two days post-surgery. For the Sox9 KO
animals, functional recovery started as early as one week afterwards, and no side
preference was noted by the second week. However, in the control group, the progress of
functional recovery was much slower. A two-way repeated measures ANOVA revealed
significant effects of genotype and time (p<0.0001), as well as a genotype by time
interaction (p=0.0024). The * symbol denotes a significant difference between genotypes
by a Bonferroni post-hoc test (p<0.05, n=12 for Control, n=14 for Sox9 KO).
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Corner Test
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3.1.2 Cylinder test: Sensori-motor recovery after MCAO was improved in
Sox9 knockout mice compared to controls
The cylinder test was also used to examine sensori-motor function in the mice by
assessing forelimb use asymmetry. Figure 4 illustrates the cylinder test results obtained
between three days to four weeks post-stroke. Preference for placement of the forelimb
unaffected by the left-sided MCAO was notable in both groups by three days post-surgery
(as indicated by a higher asymmetry score). No preference of forelimb use was observed
as early as two weeks after MCAO in the Sox9 KO mice (asymmetry score of 0.008 ±
0.12). A repeated measurements two-way ANOVA test revealed significant effects of
genotype (p=0.0061) and time (p<0.0001), but no genotype by time interaction. Thus the
Sox9 mice exhibited overall improved sensori-motor functional recovery compared to
controls. Pre-MCAO measurements were not recorded for these mice; however, groups of
uninjured control and Sox9 KO mice were tested afterward, to ensure that neither group
showed a side preference for turning based solely on genotype (n=5 for both control and
Sox9 knockout animals, p>0.05 with a Student's t-test; data not shown).

3.1.3 Grip strength test: Recovery of paretic forelimb strength after
MCAO was improved in Sox9 knockout mice compared to controls
The grip strength test was used to assess strength of the paretic right forelimb
(innervated by the left hemisphere affected by MCAO). Figure 5 illustrates the grip
strength test results obtained before MCAO compared to three days after the surgery, and
up to four weeks post-MCAO. Reduction of grip strength was observed in all animals
three days after surgery. Sox9 KO mice managed to attain pre-injury grip strength levels of
the paretic limb over the observed testing period (exhibited 96.75 ± 3.29% of pre-injury
strength by four weeks post-MCAO, versus 83.11 ± 4.43 % in the control animals). A
repeated measurements two-way ANOVA test revealed a global genotype effect (p=0.049)
and time effect (p<0.0001), but no genotype by time interaction. Thus the Sox9 mice
exhibited overall improved recovery of motor function compared to controls.
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Figure 4: Sox9 KO mice demonstrate improved recovery of sensori-motor function
following MCAO as observed in the cylinder test. Main effects of genotype (p=0.0061) and
time (p<0.0001) were observed with a two-way repeated measures ANOVA test. The *
symbol denotes the significant effect of genotype ( n=11 for Control, n=11 for Sox9 KO).
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Cylinder Test
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Figure 5: Sox9 KO mice demonstrate improved recovery of motor function following
MCAO as observed in the grip strength test. Main effects of genotype (p=0.049) and time
(p<0.0001) were observed with a two-way repeated measures ANOVA test. The * symbol
denotes the significant effect of genotype ( n=9 for Control, n=8 for Sox9 KO).

44

Grip Strength Test
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3.2

Effects of Sox9 ablation on structural neuroplasticity after MCAO
To determine if Sox9 ablation in mice had an effect on structural neuroplasticity

after MCAO, a BDA anterograde tract tracing experiment was used to examine the
corticorubral and corticospinal tracts originating from the uninjured motor cortex. BDAlabeled fibers present at the level of the red nucleus and cervical spinal cord were
examined and counted six weeks after the MCAO injury. The denervated side of the red
nucleus was ipsilateral to the MCAO (ipsilesional), since the corticorubral tract is
innervates primarily ipsilaterally. Tract tracing studies in uninjured rodents show that
<1% of fibers cross the midline towards the contralateral red nucleus (when BDA-labeled
fiber numbers on the contralateral side are normalized to those within the corticospinal
tract) (Z'Graggen, Metz et al. 1998; Reitmeir, Kilic et al. 2011; Herz, Reitmeir et al.
2012). The denervated side of the cervical spinal cord was contralateral to the MCAO
(contralesional), since the corticospinal tract innervates primarily contralaterally. Tract
tracing studies in uninjured rodents show that only 2-4% of the corticospinal neurons of
the sensori-motor cortex project to the ipsilateral spinal cord (Rouiller, Liang et al. 1991)
Structural plasticity was assessed by examining numbers of BDA-labeled fibers at the red
nucleus and cervical spinal cord to see if Sox9 ablation led to increased sprouting of
motor tract axons into deafferented areas.

3.2.1 Sox9 ablation led to increased structural plasticity in the
contralesional corticorubral tract after MCAO
Anatomical and physiological studies in mice have shown that the red nucleus
plays an important role in locomotion through ipsilateral input from the motor cortex, as
well as connectivity with the spinal cord, cerebellum, and thalamus (Liang, Paxinos et al.
; Roger and Cadusseau 1987; Jiang, Alheid et al. 2002). Figure 6A is a schematic
highlighting the BDA injection into the right motor cortex, and the two corticorubral
pathways of interest (with the black line representing normal innervation, and the dotted
line extending to the denervated side). BDA-labeled fibers at the level of the
parvocellular red nucleus on both sides were quantified six weeks post-MCAO.
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Our results revealed significantly higher numbers of BDA-labeled corticorubral
fibers present at the ipsilesional (deafferented) red nucleus in Sox9 KO mice by a
Student's t-test (p<0.05, average of 3.5 ± 1.402 fibers for controls and 11.36 ± 1.588
fibers for Sox9 KO mice). In order to control for labeling efficiency differences among
animals, this number was normalized to the number of BDA-labeled fibers present on the
contralesional side (which were not significantly different between Sox9 KO and control
animals). The resulting percentages of BDA-labeled corticorubral fibers present on the
ipsilesional side six weeks post-MCAO were significantly higher in the Sox9 KO mice
compared to control animals. These results suggest increased structural plasticity in the
intact corticorubral tract (contralesional) after MCAO in Sox9 KO animals. Figure 7
depicts two high quality confocal images of BDA-labeled fibers extending to SMI-32
positive cells (representative of rubrospinal cells) at the denervated parvocellular red
nucleus in Sox9 KO mice.
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Figure 6: Sox9 KO mice display increased contralesional corticorubral neuroplasticity
after MCAO compared to control animals.
A) Biotinylated dextran amine (BDA) was injected into the contralesional motor cortex
and BDA-labeled fibers were quantified at the level of the parvocellular red nucleus (RN).
(B-E) Photomicrographs of representative parvocellular red nucleus sections from control
and Sox9-ablated mice six weeks after MCAO, both contralateral and ipsilateral to the
BDA injection. Scale bar in B, D = 25µm. Scale Bar in C, E = 100 µm.
(F) Quantification of the number of BDA-stained fibers present at the ipsilesional
parvocellular red nucleus. The Sox9-ablated mice exhibited significantly higher numbers
of BDA-labeled fibers on the denervated side compared to control mice as demonstrated
by a Student's t-test (p<0.05, n=6 for Control, n=8 for Sox9 KO). (G) Percentages of
BDA labeled fibers present at the denervated ipsilesional parvocellular red nucleus
(number of BDA-labeled fibers extending to denervated side normalized to the number of
BDA-labeled fibers on the contralesional side). The Sox9-ablated mice exhibited
significantly higher percentages of BDA-labeled fibers on the denervated side compared
to control mice as demonstrated by a Student's t-test (p<0.05, n=6 for Control, n=8 for
Sox9 KO).
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Figure 7: Confocal photomicrographs depicting BDA-labeled fibers extending to
SMI-32 positive cells at the denervated (ipsilesional) parvocellular red nucleus.
(A,B) Two photomicrographs of representative ipsilesional red nucleus SMI-32 positive
cells from Sox9-ablated mice 6 weeks after MCAO. BDA fibers shown in red are from
neurons originating in the contralateral motor cortex. Scale bar in A-B = 5 µm.
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3.2.2 Sox9 ablation led to increased structural plasticity in the
contralesional corticospinal tract after MCAO
In the corticospinal tract (CST), long axons of the cortical pyramidal neurons
decussate almost completely at the pyramidal decussation within the brainstem, and over
90% of fibers project via the dorsal funiculus, to the contralateral half of the spinal cord
(Rouiller, Liang et al. 1991). Figure 8A is a schematic highlighting the BDA injection
into the right motor cortex, and the two corticospinal pathways of interest (with the black
line representing normal innervation, and the dotted line extending to the denervated
side). Injection of BDA into the right (contralesional) side of the sensori-motor cortex
resulted in clear positive staining in the dorsal funiculus of the left (ipsilesional) side of
the spinal cord. BDA-staining at the level of cervical enlargement in the ipsilesional
spinal cord (predominantly innervated side) showed no significant difference between
Sox9 KO and control groups.
Our results revealed significantly higher numbers of BDA-labeled fibers present
at the contralesional (deafferented) side of the cervical spinal cord in the Sox9 KO mice
by a Student's t-test (p<0.05, average of 9.417 ± 2.173 fibers for controls and 19.06 ±
2.325 fibers for Sox9 KO mice). In order to control for labeling efficiency differences
among animals, this number was normalized to the number of BDA-labeled fibers on the
ipsilesional side. The resulting percentages of BDA-labeled fibers present within the
deafferented contralesional cervical spinal cord were also significantly higher in the Sox9
KO mice compared to control animals (p<0.05). These results suggest increased
structural plasticity in the contralesional corticospinal tract after MCAO in Sox9 KO
animals.
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Figure 8: Sox9 KO mice display increased contralesional corticospinal neuroplasticity
after MCAO compared to control animals.
(A) Biotinylated dextran amine (BDA) was injected into the contralesional motor cortex
and BDA-labeled fibers were quantified at the level of the cervical spinal cord.
(B-E) Photomicrographs of representative cervical spinal cord sections from control and
Sox9-ablated mice six weeks after MCAO, both contralateral and ipsilateral to the BDA
injection. Scale bar in B, D = 100µm. Scale bar in C, E = 25µm (F) Quantification of the
number of BDA-stained fibers crossing the midline to the contralesional cervical spinal
cord. The Sox9-ablated mice exhibited significantly higher numbers of BDA-labeled fibers
on the denervated side compared to control mice as demonstrated by a Student's t-test
(p<0.05, n=6 for Control, n=8 for Sox9 KO). (G) Percentages of BDA labeled fibers
present within the denervated, contralesional side of cervical spinal cord (number of BDAlabeled fibers extending to denervated side normalized to the number of BDA-labeled
fibers on the ipsilesional side). The Sox9-ablated mice exhibited significantly higher
percentages of BDA-labeled fibers on the denervated side compared to control mice as
demonstrated by a Student's t-test (p<0.05, n=6 for Control, n=8 for Sox9 KO).
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3.3

Effects of Sox9 ablation on putative synaptic plasticity after MCAO
To determine if Sox9 ablation in mice had an effect on synaptic neuroplasticity

after MCAO, immunohistochemistry was used to examine glutamatergic input markers
at the deafferented red nucleus and ventral horn of the cervical spinal cord. Vesicular
glutamate transporter 1 (VGLUT1) is the major glutamate transporter of corticorubral
cells, while VGLUT2 is the major glutamate transporter of cerebellar inputs (Allen Brain
Atlas - VGlut1 in mouse brain; Allen Brain Atlas - VGlut2 in mouse brain; Varoqui,
Schafer et al. 2002; Fink, Englund et al. 2006). Thus, it was of interest to see if levels of
these important glutamatergic markers differed between genotypes, and if they correlated
with the structural neuroplasticity data. VGLUT1 and/or VGLUT2 levels within the
denervated red nucleus and cervical spinal cord were examined and counted six weeks
after sham surgeries, as well as 48 hours and six weeks after the MCAO injury in both
groups of animals. VGLUT levels were assessed to determine if Sox9 ablation led to
increased levels of glutamatergic synaptic markers (and theoretically, increased
innervation) within deafferented areas.

3.3.1 Sox9 ablation led to increased levels of VGLUT1 input markers at
the deafferented red nucleus six weeks after MCAO
Results of a One-way ANOVA followed by a Newman-Keuls post-hoc test
(Figure 9) revealed that 48 hours after MCAO, both control and Sox9 KO animals
experienced a significant loss in VGLUT1 immunoreactivity at the deafferented,
ipsilesional parvocellular red nucleus compared to sham animals (symbolized by
statistically difference groups "a" and "b" on in Figure 9). Sham animals were included
to represent normal VGLUT1 levels. However, six weeks after MCAO, Sox9-ablated
animals displayed increased VGLUT1 immunoreactivity levels (statistically the same
level as the Sham animals exhibited, denoted by the label "a" in the figure). The control
mice also experienced a significant increase in VGLUT1 levels at the ipsilesional red
nucleus from 48 hours to six weeks-post MCAO (label "c" in Figure 9), but this was
significantly lower than that measured in the sham animals and the six weeks postMCAO Sox9 KO mice.
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Figure 9: Sox9 KO mice display increased levels of VGLUT1 at the ipsilesional red
nucleus six weeks post-MCAO compared to control animals, after a significant decrease in
both groups 48 hours-post MCAO compared to shams.
Representative photomicrographs of parvocellular red nucleus sections ipsilateral to
MCAO from control and Sox9-ablated mice six weeks after a sham surgery (A, B), 48
hours after MCAO (C, D), and six weeks after MCAO (E, F). Vesicular glutamate
transporter 1 (VGLUT1) in red represents glutamatergic input mainly from the motor
cortex. SMI-32 in green represents rubrospinal neurons. Bar in A-F = 20 µm.
(G) Quantified volume of VGLUT1 immunoreactivity per volume of red nucleus section
for each animal type, and time point. There was a significant decrease in VGLUT1
immunoreactivity between Sham animals and 48 hours post-MCAO animals for both
groups. However, Sox9-ablated animals displayed increased VGLUT1 immunoreactivity
levels six weeks after MCAO (attain same level as the Sham animals exhibit), whereas the
control mice did not increase back to this normal level. The different letters a, b, and c
represent significantly different groups by One-way ANOVA, followed by a NewmanKeuls post-hoc test (p<0.05, n=3 for Sham-Control and 48 hours-Sox9 KO, n=4 for ShamSox9 KO, n=5 for 48 hours-Sox9 KO and 6 weeks-Control, n=6 for 6 weeks-Sox9 KO).
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3.3.2 Sox9 ablation did not lead to increased levels of VGLUT2 input
markers at the deafferented red nucleus six weeks after MCAO
Results of a One-way ANOVA followed by a Newman Keuls post-hoc test
(Figure 10) revealed that there were no significant differences between control and Sox9
KO animals at any individual time point. Sham animals were included to represent
normal VGLUT2 levels. However, 48 hours after MCAO, control animals experienced a
significant loss in VGLUT2 immunoreactivity at the deafferented, ipsilesional red
nucleus compared to sham animals. Both Sox9 KO and control animals exhibited
significantly increased levels of VGLUT2 from 48 hours post-MCAO to six weeks after
injury (p<0.05), but were statistically equivalent at the six weeks post-MCAO time point.

3.3.3 Sox9 ablation did not significantly change levels of VGLUT1 input
markers at the deafferented cervical spinal cord ventral horn six
weeks after MCAO
Results of a One-way ANOVA revealed that VGLUT1 levels at the deafferented,
contralesional cervical spinal cord ventral horn did not differ significantly between sham
or six weeks post-MCAO animals in Sox9 KO or control groups (Figure 11, p>0.05).
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Figure 10: Sox9 KO mice exhibit no significant loss of VGLUT2 levels at the ipsilesional
red nucleus 48 hours post-MCAO compared to sham animals, and both Sox9 knockout and
control animals experience significantly increased levels of VGLUT2 by six weeks
afterwards.
Representative photomicrographs of ipsilesional parvocellular red nucleus sections from
control and Sox9-ablated mice six weeks after a sham surgery (A, B), 48 hours after
MCAO (C, D), and six weeks after MCAO (E, F). Vesicular glutamate transporter 2
(VGLUT2) in red represents glutamatergic input from other CNS areas (cerebellar and
thalamic). SMI-32 in green represents rubrospinal neurons. Bar in A-F = 20 µm.
(G) Quantified VGLUT2 volume of immunoreactivity per volume of red nucleus section
for each animal type, and time point. There were no significant differences in VGLUT2
immunoreactivity levels between control and Sox9 KO animals at any individual time
point. There were also no significant differences between Sham and six weeks-post MCAO
groups (for control and Sox9 KO animals); However, at 48 hours post-MCAO, control
animals displayed a significant decrease in VGLUT2 immunoreactivity at the level of the
deafferented parvocellular red nucleus compared to both types of Sham animals, whereas
the Sox9 KO animals at 48 hours post-MCAO did not. At six weeks post-MCAO, both
control and Sox9 KO animals displayed significantly increased VGLUT2 levels
(statistically equal to Sham, showing normal levels) compared to their counterparts at 48
hours-post MCAO. The * symbol represents a significant difference between two groups
by One-Way ANOVA, followed by a Newman-Keuls post-hoc test (p<0.05, n=3 for ShamControl, Sham-Sox9 KO, and 48 hours-Sox9 KO, n=5 for 48 hours-Control and 6 weeksControl, n=6 for 6 weeks-Sox9 KO).
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Figure 11: VGLUT1 levels at the contralesional cervical spinal cord ventral horn do not
differ significantly between sham or six weeks post-MCAO animals in either Sox9 KO or
control groups.
Representative photomicrographs of contralesional cervical spinal cord ventral horn
sections from control and Sox9-ablated mice six weeks after a sham surgery (A, B), and
six weeks after MCAO (C, D). Vesicular glutamate transporter 1 (VGLUT1) in red
represents glutamatergic input mainly from the motor cortex. NeuN in green is a marker for
nuclei of neurons; large motor neurons of the ventral horn are evident. Bar in A-D =
100µm. (E) Quantified VGLUT1 area of immunoreactivity per area of cervical spinal cord
ventral horn section for each animal type, and time point. There were no significant
differences in VGLUT1 immunoreactivity levels between the different groups of animals
as determined by a One-Way ANOVA (p>0.05, n=4 for Sham-Control and Sham-Sox9
KO, n=5 for 6 weeks-Sox9 KO, n=6 for 6 weeks-Control).
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Chapter 4:

Discussion
This research project aimed to enhance understanding of the role of the
transcription factor SOX9 in stroke pathology and recovery. Having previously
identified SOX9 as responsible for upregulating the expression of axonal growthinhibiting CSPGs in the injured CNS, we hypothesized that decreasing levels of SOX9
would result in increased neuroplasticity, and in turn, improved functional recovery after
stroke in mice. To achieve this, we used a conditional knockout mouse model in which
exons 2 and 3 of the Sox9 were removed with a Cre-loxP system, inducible by tamoxifen
administration. It is pertinent to note that in this model, Sox9 would theoretically be
knocked out in all cell types.

4.1

The influence of SOX9 on functional recovery after stroke
The first objective of my thesis was to determine whether or not conditionally

knocking out Sox9 would alter functional recovery after stroke in mice. Three separate
behavioural tests were implemented to assess neurological and motor function after
MCAO. Used to detect sensori-motor and postural asymmetries, the corner test results
displayed perhaps the most significant example of improved sensori-motor recovery after
stroke in the Sox9-ablated mice compared to control animals. Sox9 KO mice were
exhibiting pre-injury behaviour of no side preference for turning by two weeks after
MCAO, whereas the control animals displayed significantly slower progress and lower
levels of sensori-motor recovery over the four post-injury weeks. The corner test is
known to be one of most reliable tests for detecting long-term sensori-motor dysfunction
in rodents after injury (Zhang, Schallert et al. 2002). Thus, it was encouraging that the
results to this sensitive test revealed the most prominent significant differences between
Sox9 KO and control animals out of all behavioural tests (significant effects of genotype
and time, as well as genotype-time interactions on all post-surgical weeks).
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Other important markers of functional recovery after stroke include use and
strength of the paretic limb. The cylinder test results demonstrated overall improved
functional recovery after MCAO in Sox9 KO mice compared to control animals, with
significant effects of both genotype and time in forelimb use asymmetry over the four
week post-surgical testing period, The results also suggested that Sox9 KO mice used the
unaffected and paretic forelimbs equally to explore the cylinder wall by two weeks after
MCAO (asymmetry score of 0.008 ± 0.12). The grip strength test highlighted
significantly improved recovery in strength of the paretic limb in the Sox9-ablated
animals compared to controls animals, with a significant effect of both genotype and
time. The data suggested that Sox9 KO animals achieved full recovery of grip strength
(96.8 ± 3.3%) by the end of the testing period.
The general trend seen with the behavioural test data confirmed our hypothesis
that the Sox9 KO would display improved functional recovery after MCAO compared to
control animals. It is of interest to note that mice, in general, experience endogenous
recovery to a remarkable degree after stroke (in comparison to humans). It is a unique
characteristic of the lissencephalic rodent brain that allows mice to survive larger strokes
in considerable numbers (Carmichael 2005). Along with higher survival rates, the timecourse of post-stroke recovery is often much shorter in rodents than in humans (Murphy
and Corbett 2009). This implies that decreasing levels of SOX9 within the mice improved
and augmented the already relatively high levels of endogenous sensori-motor recovery.
It is possible that decreasing levels of SOX9 affects a few different processes that, in
combination, produce significant functional improvements seen in the ubiquitous Sox9
knockout mice. As discussed in the introduction, ample evidence in the literature (and
work completed by our research group) led to our hypothesis that lower SOX9 levels, and
in turn lower CSPG levels, could result in increased neuroplasticity. Therefore, after
behavioural testing, examining neuroplasticity in these animals was our primary focus.
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4.2

The influence of SOX9 on neuroplasticity after stroke
The two main mechanisms for neuroplastic change and reorganization after stroke

are thought to be the formation of new neuronal circuitry, and the
unmasking/strengthening of existing pathways (Soleman, Yip et al. 2012). Thus the
second objective of my thesis was to evaluate structural and synaptic neuroplasticity after
MCAO in mice, and compare between Sox9-ablated mice and controls. There are many
ways to assess neuroplasticity; however, the two methods used in this work were tracttracing of the contralesional corticorubral and corticospinal pathways, as well as
immunohistological quantification of glutamatergic input synaptic markers at
deafferented CNS areas relevant to motor function.

4.2.1 Examination of structural neuroplasticity after stroke
Tract-tracing findings supported our hypothesis that the Sox9-ablated mice would
exhibit increased structural neuroplasticity after MCAO compared to controls. I
examined labeled axons of neurons originating in the uninjured side of the sensori-motor
cortex, and focused on two areas of descending projections that are very relevant to
motor function: the red nucleus in the midbrain and cervical enlargement of the spinal
cord. The literature shows that in control animals, these predominantly unilateral
connections become increasingly bilateral after stroke, as contralesional corticofugal
axons sprout to innervate deafferented areas (Lee, Kim et al. 2004; Zai, Ferrari et al.
2009).
In the present study, significantly higher numbers (and overall percentages, when
controlling for labeling efficiency) of BDA-labeled fibers were found within the
deafferented red nuclei and cervical spinal cords of the Sox9 KO animals compared to
controls animals six weeks after MCAO. This indicates that conditionally knocking out
Sox9 significantly enhanced the endogenous structural plasticity of the contralesional
corticorubral and corticospinal tracts seen in control animals. This is likely due to a)
increased sprouting of contralaterally projecting corticorubral axons that normally
contribute only minimally (<1%) to corticorubral inputs (Z'Graggen, Metz et al. 1998;
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Reitmeir, Kilic et al. 2011; Herz, Reitmeir et al. 2012), and b) increased sprouting of
ispilaterally projecting corticospinal axons that normally contribute only minimally (24%) to corticospinal inputs (Rouiller, Liang et al. 1991).. The growth of corticofugal
fibers across the midline to reach deafferented areas may still be a formal possibility;
however, sprouting of uninjured axons that were already within the deafferented areas
may be more likely to contribute to the improved function recovery of the Sox9 KO mice,
since axon growth is a relatively slow process (Cho, Yang et al. 2005).
Whether it was an increase in collateral connections, or an elaboration of
unilateral connections to the denervated areas that were present before injury, increased
contralesional corticofugal structural neuroplasticity was observed in the Sox9 KO
animals compared to controls. We hypothesize that this was due to the consequently
lower levels of CSPGs (both in the diffuse extracellular matrix and dense peri-neuronal
nets) in the knockout animals, which would have theoretically created a CNS
environment more permissive to axon sprouting. The increased structural plasticity of
uninjured corticofugal fibers may have contributed to the improved functional recovery
observed in the Sox9 KO mice. Further studies might include electrophysiological
experiments to determine whether or not this increased fiber growth into deafferented
area does, in fact, translate into increased functionality.

4.2.2 Examination of synaptic neuroplasticity after stroke: glutamatergic
input markers at the denervated red nucleus
If the improved functional recovery observed in the Sox9 KO mice is due the
increased reactive sprouting of corticofugal projections (demonstrated by the BDAlabeling) , then one would predict that the Sox9 KO mice would also demonstrate
increased expression levels of synaptic proteins in the deafferented red nucleus and
cervical spinal cord compared to controls. Thus, we examined the expression levels of
presynaptic markers in the ipsilesional red nucleus and contralesional cervical spinal
cord. The literature suggests that VGLUT expression is used endogenously to directly
regulate the extent of glutamate release, which presents a presynaptic mechanism to
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control excitatory transmission for synaptic refinement and plasticity (Wilson, Kang et al.
2005). Therefore, a change in presynaptic VGLUT levels suggests a change in excitatory
innervation. The quantification of synaptic markers has been used in other central
nervous system injury studies to examine probable changes in innervation at deafferented
areas (e.g. the spinal cord) (Apostolova, Irintchev et al. 2006; Zhao, Zhao et al. 2013).
Our tract tracing findings displayed an increase in fibers projecting from the uninjured
sensori-motor cortex to the deafferented parvocellular red nucleus in the Sox9 KO
animals, so it was of interest to see if this corresponded with an increase in VGLUT
expression.
As discussed in the introduction, the corticorubral tract is composed of
glutamatergic neurons, with VGLUT1 as the predominantly expressed vesicular
glutamate transporter (Allen Brain Atlas -VGlut1 in mouse brainBromberg, Penney et al.
1981). The immunohistological analysis revealed that both Sox9 KO and control mice
experienced loss of VGLUT1 levels at the deafferented parvocellular red nucleus by 48
hours post-MCAO. The small, however significant, increase in VGLUT1 levels
exhibited by the control animals at six weeks post-MCAO testifies to the neuroplasticity
that normally occurs post-stroke. The Sox9 KO mice exhibited full restoration of
VGLUT1 levels by six weeks post-MCAO (statistically equivalent to sham levels), which
suggests a heightened level of neuroplasticity in these mice compared to controls. The
significantly higher VGLUT1 levels at the deafferented red nucleus in the knockout
animals corresponded with an increased presence of fibers projecting from the
contralesional sensori-motor cortex. Again, we hypothesize that this occurred due to
lower levels of CSPGs (both in diffuse extracellular matrix and dense peri-neuronal nets),
which created a CNS environment more permissive to neuroplasticity and synapse
formation.

Further experiments may include co-staining for BDA and VGLUT1 at the
deafferented parvocellular red nucleus. Co-localization would suggest that the
contralesional corticorubral fibers expressed the presynaptic glutamatergic transporter
proteins necessary to make functional connections with deafferented neurons. Another
useful experiment to further provide evidence of putative functional synapses would
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involve co-staining for presynaptic VGLUT1 proteins and corresponding post-synaptic
density proteins (PSD). PSD-95 is the most ubiquitous and best characterized of the
glutamatergic PSD proteins, and is thought to be fundamentally important in anchoring
AMPA (α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors at the postsynaptic membrane (Bruneau, Esteban et al. 2009). Since proper post-synaptic protein
expression is also essential to synapse functionality, co-localization of VGLUT1 and
PSD-95 at cell membranes of interest would further suggest potential synapse
functionality. Again, electrophysiological studies would be ideal to reinforce this
hypothesis, and confirm the existence of functional connections.
VGLUT2 levels at the deafferented red nucleus tell a somewhat different story.
Another major glutamatergic input to the red nucleus extends from the deep cerebellar
nuclei of the cerebellum; these projections are predominantly VGLUT2-positive (Allen
Brain Atlas - VGlut2 in mouse brain; Fink, Englund et al. 2006). Efferent projections to
the parvocellular red nucleus also extend from the posterior thalamic nuclei. Since
VGLUT2 has been established as the most abundant VGLUT isoform of thalamic nuclei,
this is likely a source of VGLUT2 innervation as well (Moechars, Weston et al. 2006;
Barroso-Chinea, Castle et al. 2007). Together, cerebellar and thalamic glutamatergic
innveration at the red nucleus play a role in movement coordination and proper
integration of sensori-motor information (Roger and Cadusseau 1987; Siegel 2010)
Immunohistological analysis revealed that only control animals experienced a
significant decrease in VGLUT2 levels at the deafferented red nucleus by 48 hours after
stroke. Since the red nucleus and cerebellum are both in areas of the brain that are not
directly damaged by MCAO, it is unlikely that this loss of VGLUT2 levels was due to
lost cerebellorubral connections. The thalamus does not receive direct blood supply from
the MCA either; however, it is supplied by branches of the internal carotid artery, which
is a vessel manipulated during the MCAO procedure. This, in combination with its
relative proximity to the infarcted area, may have put the thalamus at risk for damage
from ischemia or secondary processes (Popp, Jaenisch et al. 2009). As such, there is a
chance that some degree of ischemic damage occurred, leading to a slight decrease in
thalamorubral VGLUT2-positive input to the red nucleus. In the Sox9 KO animals, there
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was no significant decrease in VGLUT2 input at 48 hours post-MCAO, which may have
been due to some sort of neuroprotective effect caused by Sox9 ablation. However,
similar evidence for neuroprotection was not observed in the VGLUT1 analyses. In any
case, it would be advantageous to complete future experiments to examine the possibility
of neuroprotection (such as retrograde tract tracing from deafferented areas) and compare
between genotypes.
Finally, both Sox9 KO and control animals experienced a significant increase in
VGLUT2 levels at the deafferented parvocellular red nucleus from 48 hours after injury
to reach normal levels by six weeks post-MCAO. In the control animals, this may have
once again been due to endogenous levels of neuroplasticity. Since the control animals
did not attain normal levels of VGLUT1 expression at the deafferented red nucleus by six
weeks after MCAO, an increase in excitatory innervation from other areas may have been
a more needed and encouraged compensatory response. The lack of a significant
difference between control and Sox9 KO animals by six weeks after MCAO may indicate
that VGLUT2-positive innervation (most likely of thalamic and cerebellar origin) at the
deafferented red nucleus did not play a major role in the improved functional recovery
seen in the knockout animals.

4.2.3 Examination of synaptic neuroplasticity after stroke: glutamatergic
input markers at the denervated cervical spinal cord ventral horn
As discussed in the introduction, the corticospinal tract is composed of
glutamatergic neurons, with VGLUT1 as the predominant vesicular glutamate transporter
expressed (Allen Brain Atlas -VGlut1 in mouse brainBromberg, Penney et al. 1981;
Varoqui, Schafer et al. 2002). The immunohistological analysis of VGLUT1 levels at the
deafferented cervical spinal cord ventral horn revealed that there were no significant
differences between control or Sox9 KO animals six weeks post-MCAO. VGLUT1
levels at six weeks-post MCAO in both groups of mice were also were statistically
equivalent to those exhibited by sham animals. It is interesting to note that, unlike the
VGLUT1 immunohistochemistry analysis at the red nucleus, this data does not correlate
with the tract tracing findings; the BDA experiments showed that more fibers from the
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contralesional cortex were present within the deafferented cervical spinal cord in the Sox9
KO animals six weeks after MCAO compared to controls.
This may have resulted for a number of reasons. It is possible that other
glutamatergic inputs to the deafferented cervical spinal cord ventral horn played a role in
the improved functional recovery seen in the knockout animals. Since putative
contralesional corticorubral VGLUT1 innveration was significantly higher in the
deafferented red nucleus of the Sox9 KO mice six weeks after MCAO, this may have
translated into improved function due to enhanced rubrospinal activity. The rubrospinal
tract is VGLUT2 positive, which was not analyzed at the deafferented cervical spinal
cord in the present study (Liang, Paxinos et al. 2012Liang, Paxinos et al. 2012). It is
also necessary to note that evidence of structural plasticity with tract tracing does not
necessarily mean that functional synapses were formed; VGLUT proteins may not have
been present in the axon terminals of the BDA-labeled fibers to create functional
synapses. Therefore, one explanation for these data is that increased functional
connectivity of the contralesional corticospinal tract to the deafferented cervical spinal
cord may not have occurred to play a role in the improved functional recovery exhibited
by the knockout mice.

On the other hand, Since VGLUT expression at the cervical spinal cord ventral
horn was measured over a much larger area than it was at the red nucleus, a difference
between genotypes may not have been large enough to be detected and to achieve
statistical significance. Perhaps a difference in VGLUT1 staining due to 2.957 ± 0.5663
percent of overall labeled contralesional fibers present at the deafferented cervical spinal
cord in the control mice versus 5.856 ± 0.7764 percent in the Sox9 KO mice was not
substantial enough to display a significant difference between genotypes (when
immunoreactivity of all sources of VGLUT1 on all neurons of the cervical spinal cord
ventral horn was measured). Arguably, a more accurate way to examine possible
synapses of interest is to count puncta of synaptic markers around specific cells of
interest (e.g. motor neurons in the spinal cord and rubrospinal neurons in the red
nucleus). Interestingly enough, recent work done by our research group has shown that
numbers of VGLUT1 puncta surrounding motor neurons of the deafferented cervical
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spinal cord ventral horn are significantly higher in the Sox9 KO animals compared to
those in the controls after stroke. Thus, it is possible that this difference was simply
diluted by the large area that VGLUT1 immunoreactivity was measured over the
deafferented cervical spinal cord ventral horn in the present study. Immunohistological
co-localization of VGLUT1 and BDA would be another beneficial follow-up experiment
to further establish evidence of putative synapses of the contralesional corticospinal tract.
VGLUT1 and PSD-95 co-localization would also give insight as to whether or not both
pre-and post-synaptic proteins were aligning for proper synapse functionality. Again,
electrophysiological studies would be ideal to elucidate these findings.

4.3

Conclusions
Overall, Sox9 KO animals exhibited improved functional recovery after a 30

minute MCAO compared to control animals. We hypothesized that this may occur due to
increased neuroplasticity in the Sox9 KO animals, since previous studies by our research
group showed that Sox9 ablation caused a decrease in the expression of axon growthinhibiting CSPGs in the CNS. Tract-tracing findings supported our hypothesis: the Sox9ablated mice exhibited increased contralesional corticofugal structural neuroplasticity
compared to control mice when BDA-labeled fibers were analyzed at the denervated red
nucleus and cervical spinal cord after MCAO.
Putative synaptic neuroplasticity was examined with markers for presynaptic
glutamatergic input within the deafferented areas. Sox9 KO animals exhibited
significantly higher levels of VGLUT1 at the deafferented red nucleus by six weeks after
MCAO compared to control mice. Since VGLUT1 is the main VGLUT isoform of the
corticorubral tract, this data correlated nicely with the tract tracing findings to support the
hypothesis. Higher levels of synaptic neuroplasticity in the Sox9 KO animals for the
thalamorubral, cerebellorubral, or corticospinal tracts (which are also important for motor
function) were not evident with the presented immunohistological analyses. Further
studies (e.g. counting puncta or co-localizing synaptic markers on cells of interest, as well
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as electrophysiological experiments) would be very beneficial to explore neuroplasticity
further.
The improved functional recovery observed in the Sox9 KO mice is certainly
interesting. Evidence of increased contralesional corticorubral and corticospinal
plasticity is encouraging, and correlates nicely with the previously observed lower levels
of CSPGs and PNNs in the Sox9 KO mice central nervous system. Further unraveling the
exact mechanisms that elicited the improved functional recovery observed in Sox9ablated mice after stroke could lead to the development of novel stroke treatments for
humans.
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